Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
7-30-2013 12:00 AM

Reproducibility of Hyperpolarized Xenon-129 Magnetic
Resonance Imaging
Nikhil Kanhere, The University of Western Ontario
Supervisor: Dr. Grace Parraga, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Engineering
Science degree in Biomedical Engineering
© Nikhil Kanhere 2013

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Bioimaging and Biomedical Optics Commons

Recommended Citation
Kanhere, Nikhil, "Reproducibility of Hyperpolarized Xenon-129 Magnetic Resonance Imaging" (2013).
Electronic Thesis and Dissertation Repository. 1376.
https://ir.lib.uwo.ca/etd/1376

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

REPRODUCIBILITY OF HYPERPOLARIZED XENON-129
MAGNETIC RESONANCE IMAGING
(Thesis format: Monograph)

by

Nikhil Kanhere, B.E.

Graduate Program in Biomedical Engineering

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Engineering Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Nikhil Kanhere 2013

Abstract
Spirometry and plethysmography provide gold standard measurements of obstructive
lung disease, although these are global measurements of lung function made at the
mouth, of a highly regionally heterogeneous disease. Hyperpolarized

129

Xe magnetic

resonance imaging (MRI) is a non-invasive, non-radiation-based imaging tool for
visualizing regional lung structure and function. However, the reproducibility of

129

Xe

MRI measurements has not yet been studied or determined. Hence, in this thesis, we
evaluated the reproducibility of

129

Xe MRI using quantitative measurements such as

ventilation defect percent (VDP). We showed that

129

Xe VDP had high intra-observer

and inter-observer reproducibility for repeated scans acquired on the same-day and after
1-week and its reproducibility was comparable to that of 3He VDP.

129

Xe VDP showed

strong and significant correlations with pulmonary function tests.

These results

suggested that 129Xe VDP is reproducible over short periods of time and can be a reliable
measurement to study pulmonary function in imaging studies.

Keywords: Hyperpolarized, 129Xe, 3He, magnetic resonance imaging, chronic obstructive
pulmonary disease, reproducibility, functional lung imaging, ventilation defects
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CHAPTER 1: INTRODUCTION
During the last two decades, hyperpolarized noble gas magnetic resonance

imaging (MRI) has emerged as an important tool to study pulmonary diseases like
chronic obstructive pulmonary disease (COPD) and asthma. Understanding the anatomy
of the lung and the physiological changes that take place after the onset of disease is
critical for understanding the mechanism of disease progression and improvements after
therapy as well as the implementation of new diagnostic tools. The objective of Chapter
1 is to provide a motivation for the work presented in the following chapters as well as
provide an overview of pulmonary anatomy, pathology of obstructive lung disease, the
diagnostic tools and the different imaging modalities currently used to evaluate
pulmonary disease.

1.1

Burden of Pulmonary Disease
According to the World Health Organizations’ global burden of disease 2004

update, respiratory diseases were responsible for 6.8% of all male and 6.9% of all female
deaths worldwide.6 Chronic obstructive pulmonary disease (COPD) was the 4th leading
cause of death worldwide, and accounted for three million or 5.1% of all deaths
worldwide while asthma was responsible for another 0.287 million or 0.5% of all deaths
worldwide.6 It is predicted that by 2030, COPD will be the 3rd leading cause worldwide
accounting for 8.6% of all deaths as shown in Table 1.1.7 It was estimated that the
prevalence of COPD was 63.6 million and asthma 234.9 million worldwide in 2004.6
Asthma was the leading chronic disease in children in industrialized countries.8 COPD
and asthma were the 10th and 13th leading causes of moderate and severe disability in
2004 responsible for 26.6 million and 19.4 million disabilities worldwide respectively.6
In Canada, respiratory diseases were the 3rd leading cause of death just below
cardiovascular disease and cancer in 2005.1 As shown in Figure 1.1, respiratory diseases
were responsible for 8.7% of all male deaths and 8.6% of all female deaths in Canada
with COPD alone accounting for 4.5% and 4% of deaths respectively.1 The economic
burden of respiratory diseases is enormous, with COPD and asthma accounting for 3%
and 1% of all hospitalizations in Canada in 2004-05.1

As shown in Figure 1.2,

2

respiratory diseases were ranked 8th in terms of the total healthcare costs in Canada
accounting for just over 5.6 billion dollars in 2000.1

In 2010, the cost rose to

approximately 12 billion dollars, and in the best case scenario, the number is expected to
rise to just over 24 billion dollars in 2030.9 Asthma was the number one cause for
emergency room visits in Canada in 1994.8 There were 3.1 million people suffering from
asthma and just over 1.65 million from COPD in Canada in 2010.9

Table 1.1 Leading causes of death worldwide 2004 and predicted values in 2030.
Adapted from World Health Organization. The global burden of disease: 2004 update6
and World Health Organization. World Health Statistics7
2004
Disease

2030
Deaths
(%)

Rank

Rank

Deaths
(%)

Disease

Ischaemic heart
disease

12.2

1

1

14.2

Ischaemic heart
disease

Cerebrovascular
disease

9.7

2

2

12.1

Cerebrovascular
disease

Lower Respiratory
Tract infections

7.1

3

3

8.6

COPD

COPD

5.1

4

4

3.8

Lower Respiratory
Tract infections

3

Figure 1.1 Proportion of all deaths for men (A) and women (B) in Canada in 2005
Reproduced with permission from Life and Breath: Respiratory Disease in Canada1
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Figure 1.2 Total economic burden of respiratory diseases in Canada in 2000
Reproduced with permission from Life and Breath: Respiratory Disease in Canada1
Note: Respiratory infections include lower and upper respiratory tract infections, otitis
media and tuberculosis. Respiratory disease includes asthma, COPD and other diseases of
the respiratory system (excluding lower and upper respiratory tract infections, lung
cancer and tuberculosis), Total Respiratory is a sum of Respiratory infections and
Respiratory disease (excludes lung cancer)
Recent studies have shown that the prevalence of COPD is actually much greater
than previously believed, with a reported 9-10% of adults aged 40 years or higher having
COPD worldwide.10,11 Studies have also shown that of these individuals who were
determined to have COPD, only 19% were previously diagnosed and treated.12 These
studies suggest that COPD is highly under-diagnosed and the majority of patients do not
have a diagnosis or a treatment plan for the disease. Reports from 1979 in Canada
showed 2.3% of the population suffered from asthma, whereas in 2004, this number
jumped to 8.4% of the population.8 These results suggest that there is an immediate need
to develop new imaging tools for early detection and diagnosis of these respiratory
diseases in the future.
In the following sections, I will be describing the anatomy of the lung, the nature
of obstructive lung disease as well as the gold standard and imaging modalities currently
used for pulmonary disease diagnosis.
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1.2

Lung Structure and Function
Human cells obtain most of their cellular energy in the form of adenosine

triphosphate (ATP) from glucose through a process called as cellular respiration.13,14
Oxygen is required by the cells for respiration and carbon dioxide is formed as a
byproduct.13,14

Hence there is a need for transfer of oxygen from the external

environment into the body and carbon dioxide from the body to the external environment.
The main organ responsible for this gas exchange with the external environment is the
lung and the respiratory system assists in this process. The respiratory system consists of
the oral and nasal cavities, the paranasal sinuses, the pharynx, the larynx, the trachea, the
bronchi and their smaller branches, and the lungs, which contain the gas exchange
chambers, called the alveoli.13 Functionally the respiratory structures are divided into
two zones- the conducting and the respiratory zones as shown in Figure 1.3.2 The
conducting zone extends from the top of the trachea to the beginning of the respiratory
bronchioles; and has no capacity for gas exchange with the blood as these airways are not
lined with alveoli. The respiratory zone extends from the respiratory bronchioles down; it
contains alveoli and is the region of the lungs responsible for gas exchange with the
blood.14

6

Figure 1.3 Schematic of the human airway tree by generation (Image is not to scale)
Image adapted from West JB, Respiratory Physiology; The Essentials2
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1.2.1

The Conducting Zone
The organs that make up the conducting zone filter, humidify and warm the air

passing from the external environment to the lungs. As shown in Figure 1.3, the airways
consist of a series of branching tubes that become shorter, narrower and more numerous
through the generations of airways (deeper in the lung). The airways have about 23
generations of dichotomous branching.15 Generation number zero, or the trachea, divides
into the right and left main bronchi, which in turn divide into lobar, followed by
segmental bronchi.2 This process continues until the terminal bronchioles, which are the
smallest airways without alveoli, and the last generation of airways included in the
conducting zone.2 The airways of conducting zone do not partake in gas exchange as
these airways are not lined with alveoli, and hence the volume of gas present in the
conducting zone is called the anatomical dead space which is approximately 150 ml in a
healthy adult.2
The flexible trachea, or windpipe, descends through the larynx, through the neck
and into the mediastinum.13 A study by Kamel et. al using computed tomography (CT)
scans showed that the average tracheal length in males was 105mm while that in females
was 98mm with males having an average tracheal volume of 36 cm3 and females 24
cm3.16

The wall of the trachea contains 16-20 C-shaped rings of hyaline cartilage

connected by membranes of fibro-elastic connective tissue, enabling the trachea to be
flexible enough to permit bending and elongation during inhalation and exhalation, but
preventing it from collapsing due to the changes in pressure during breathing.13 All the
air moving in and out of the lungs must pass through the trachea which divides into
generation one of the airways or the two main bronchi.
The right and left main bronchi originate from the trachea and are also called the
primary bronchi. The left and the right main bronchi are responsible for transport of gas
from the trachea to their respective lungs.

The main bronchi further divides into

generation two of the airway tree or the lobar bronchi. The human lungs are divided into
several lobes- three on the right and two on the left.13 There is one lobar bronchus
supplying each lobe, hence a total of five lobar bronchi exist. The lobar bronchi further
divide into generation three or the segmental bronchi, which in turn repeatedly divide into
smaller bronchi till about 23 generations. The generations smaller than 1mm in diameter
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are called bronchioles (“little bronchi”) and the smallest of the bronchioles, known as the
terminal bronchioles, are less than 0.5mm in diameter.13 The terminal bronchioles are the
last generation of airways of the conducting zone and hence the last generation of airways
that do not participate in gas exchange and are found around generation 16.2 They further
divide into the respiratory bronchioles which are the first respiratory zone structures.
1.2.2

Respiratory Zone
The respiratory zone is the last part of the airway tree, distinguished from the

conducting zone by the fact that the walls of the airways are lined by the air-exchange
chambers called the alveoli. The first generation of airways in the respiratory zone,
called the respiratory bronchioles (generations 17-19 of the airway tree) have scattered
alveoli protruding from their surface.13 The respiratory bronchioles lead into the next
generation of airways known as the alveolar ducts. The alveolar ducts are straight ducts
whose walls are almost entirely covered with alveoli.13 The alveolar ducts lead into
terminal clusters of alveoli called alveolar sacs.13 The alveolar sacs are a group of
alveoli. The opening from an alveolar duct into an alveolar sac is called the atrium or
“entrance chamber”.13 The alveoli are tiny hollow sacs whose openings are continuous
with the lumens of the airways.14 The alveoli are the location where the actual gas
exchange occurs. A study by Ochs et al.17 estimated that the mean alveolar number in
human lungs was 480 million and was closely related to total lung volume with larger
lungs having significantly more alveoli. The study also reported that the mean size of an
alveoli was constant (4.2 x 106 µm3) irrespective of the size of the lungs. In this part of
the respiratory zone, the alveolar walls contain capillaries and a very small interstitial
space.14 In many places, this interstitial space is completely absent.14 Hence, the blood
within the alveolar-wall capillary is separated from the air within the alveolus by an
extremely thin barrier (0.2 µm, compared with the 7µm diameter of an average red blood
cell).14 For a healthy individual, the total surface area of the alveoli in contact with the
capillaries is roughly the size of a tennis court.14 The large surface area coupled with the
thinness of the barrier allow for the rapid exchange of large quantities of oxygen and
carbon dioxide by diffusion. The rate of diffusion of gases across the membrane is
described by Fick’s law for diffusion, as shown in equation (1):
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Diffusion =

A ⋅ D ⋅ ( P1 − P2 )
T

(1)

where, A is the surface area of the lung for diffusion, D is the diffusion coefficient of gas,
P1-P2 is the partial pressure difference of the gas across the alveolar capillary membrane,
and T is the thickness across the alveolar capillary membrane. The gas diffusion rate is
therefore directly proportional to the surface area of the lung, the diffusion coefficient of
the gas and the partial pressure difference, and inversely proportional to the thickness
across the lung membrane. As the total surface area of all alveoli in an average pair of
lungs is 140 square meters13, and the thickness of the interstitial space is extremely small
(0.2 µm)14, the efficiency of gas exchange is high. The oxygen flows from an area of
high partial pressure (inside the alveoli) to an area of low oxygen partial pressure
(pulmonary capillaries), hence the oxygen is transported from the external environment to
the blood through the respiratory system.

1.3

Obstructive Lung Disease
Obstructive lung disease (OLD) includes several conditions including obstructive

chronic bronchitis, emphysema and asthma18 and is characterized by airway obstruction,
inflamed and easily collapsible airways, obstruction to airflow and problems exhaling.
Of these, COPD is divided into chronic bronchitis and obstructive emphysema, or a
combination of these occurring together.18 Asthma is an inflammatory disease of the
airways, although there is a lot of controversy regarding the best definition of asthma as it
is a clinically complex condition.19,20
1.3.1

Chronic Obstructive Pulmonary Disease
COPD is a category of obstructive lung disease, found mainly in smokers,

characterized by difficulty in moving air into and out of the lungs, or obstruction to the
flow of air. In the Global Initiative for chronic obstructive pulmonary disease guidelines,
COPD is defined as “A disease state characterized by progressive development of airflow
limitation that is not fully reversible. The airflow limitation is usually progressive and
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usually results from an abnormal response of the lungs to noxious particles or gases.”21
Cigarette smoking, while not the only factor leading to COPD, is the main source of the
inhaled noxious particles that leads to its development. Both environmental and genetic
factors also contribute to the development of COPD. Although only 10-15% of smokers
actually go on to develop obstructive lung disease,22 active, sustained cigarette smoking
contributes to the origin of COPD in more than 90% of the subjects.23 Genetic disorders
such as alpha-1 antitrypsin deficiency have been shown to cause emphysema.24,25
Although not all smokers develop airflow limitation, studies have shown that cigarette
smoking is associated with inflammation in both the large and small airways,26,27 as well
as the lung parenchyma28 in smokers with normal forced expiratory volume in one
second (FEV1), which is a standard measure for diagnosis of airflow limitation and will
be explained in detail in the next part of this chapter. The disease that occurs within the
airways is called chronic bronchitis, and that which occurs in the lung parenchyma is
called emphysema, which are independent diseases that may manifest together or in
isolation. However, the same agents that cause chronic bronchitis- mainly smoking- also
cause emphysema, which is why these two diseases frequently occur together.
Chronic bronchitis is one of the conditions associated with COPD and is
characterized by excessive mucus production in the bronchi and chronic inflammatory
changes in the small airways.14 So significant is cigarette smoking in the development of
chronic bronchitis that this disease would be an insignificant health problem if cigarettes
were unavailable. Inhaled irritants (example from cigarette smoking) are responsible for
prolonged secretions of excess mucus by the mucosa of the lower respiratory passages,
leading to inflammation and fibrosis (formation of scar tissue) of this mucosa. This
causes an obstruction in the airways because of an accumulation of mucus in the airways
and thickening of the inflamed airways.14 The obstruction and inflammation severely
impair ventilation and gas exchange.

Figure 1.4 shows a normal airway with no

inflammation or over-secretion of mucus in the lumen of the airway, as well as an airway
inflamed due to chronic bronchitis, with excessive secretion of mucus causing a decrease
in the diameter of the airway leading to difficulty in ventilation.

Infections also

frequently occur in these patients because bacteria and viruses thrive in the stagnant pools
of mucus. Coughing is persistent and productive in these patients. Patients with chronic
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bronchitis are sometimes called “blue bloaters” because lowered blood oxygenation often
results in cyanosis (bluish discoloration of the skin) and other symptoms of right heart
failure. However, the degree of dyspnea in patients suffering from chronic bronchitis
alone is usually moderate compared to patients suffering from emphysema alone.13
From the trachea to the alveolar sacs, as the airway generations increase, the
number of airways increases rapidly due to the dichotomous branching pattern.15 As the
total number of airways increases, although they become narrower at each generation, the
total cross-sectional area at each generation increases. Although it would be expected
that the resisitance to the flow of air would increase as the radius of the individual
airways decreases according to Poiseuille’s equation (resistance of a single tube is
inversely proportional to the 4th power of the radius of the tube), this is not observed
because the number of airways and their total cross-section area increases rapidly. Since
all the airways are arranged in parallel and the resistance of parallel circuits is added as
reciprocals, small airways (<2 mm in diameter) have a very small resistance to the flow
of air. This fact was confirmed by Hogg et. al.29 who showed that in healthy subjects, the
small airways contributed very little to the total airway resistance. They also reported
that in subjects with mild and severe emphysema, there was an increase in the resistance
of the small airways (<2mm in diameter) with no increase in the total lung resisitance. It
was shown that the elevated resistance was due to mucus plugging and narrowing and
obliteration of the small airways. They defined this condition as “small airways disease”
and found that while this condition affected ventilation distribution and gas exchange, it
did not change the results of the pulmonary function tests designed to diagnose
obstruction in the airways. By the time the total airway resistance elevated to a to a level
recogized by the pulmonary function tests, the obstruction would be much more severe
that generally thought. A more recent study by Hogg et. al. showed that progression of
COPD from Global initiative for chronic Obstructive Lung Disease (GOLD) stage 0
(explained in the next part of the chapter) to GOLD stage 4 was most strongly correlated
with thickening of the airway wall caused by a repair or remodelling process.4 The
degree to which the lumen was filled with mucus and the extent of inflammatory
response was more weakly assocated with disease progression. Figure 1.5.A shows a
normal healthy small airway, Figure 1.5.B shows a small airway partially filled with
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mucus, Figure 1.5.C shows an airway with an active inflammatory process, where the
exudate extends into the lumen, Figure 1.5.D shows an airway that has been narrowed by
secretion of mucus in the peribronchiolar space.
Emphysema is characterized by a permanent irreversible enlargement of the
alveoli, caused by the deterioration of the alveolar walls13 and by the atrophy and
collapse of lower airways- those from the terminal bronchioles to the lower generations.14
The disease is associated with chronic inflammation and increased activity of lung
macrophages, whose lysosomal enzymes are responsible for destroying the alveolar walls
and breaking down elastin.13 Cigratte smoking is the single most important factor in this
process as it stimulates the release of proteolytic enzymes and destroys other enzymes
that usually protect the lung against these proteolytic enzymes.14 Figure 1.5.E shows
normal lung parenchyma in a healthy non-smoker, Figure 1.5.F shows moderate
emphysema and Figure 1.5 .G shows severe tissue destruction in severe emphysema. As
can be observed from Figures 1.5.E-G, as a result of alveolar-wall loss, adjacent alveoli
fuse to form fewer but larger alveoli thus reducing the total surface area available for
diffusion and hence for gas exchange.14 Morever, since the tissue destruction is not
consistent throughout the lungs, some areas may receive little amount of air and sufficient
amount of blood supply while others show the opposite pattern leading to ventilationperfusion inequality. Chronic inflammation also leads to fibrosis and the lungs become
progressively less elastic, making expiration difficult and exhausing.13 In these patients,
the bronchioles open during inspiration but collapse during expiration leading to a
condition know as “gas trapping” where huge amounts of air get trapped in the alveoli
leading to a “barrel chest” apperance due to enlargement of the lungs. Damage to the
lung capillaries increases the resistance in the pulmonary vascular circuit, forcing the
heart’s right ventricle to enlarge through overwork.13 Emphysema is usually divided into
two distinct forms: centrilobar and panlobar.24

Centrilobar emphysema is mainly a

disease of the upper lobes and the apices within the upper and lower lobes.24 In contrast,
panlobar emphysema shows a more homogeneous pattern and is mainly observed in the
lower lobes. Studies have shown that there is a realtionship between smoking and
centrilobular emphysema, but not with panlobar emphysema, which may be associated
with genetic disorders such as alpha-1 antitrypsin deficiency.24,30,31
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Figure 1.4 Schematic of the human airways and alveoli in healthy volunteers and subjects
with COPD.
The airways of the COPD subject on the right shows inflammation and mucus plugging
and the alveoli show extensive emphysema
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Figure 1.5 Small Airways Disease and Emphysema in COPD
(A) A healthy airway with unobstructed lumen (B) An airway with lumen partially filled
with mucus (C) Acutely inflamed airway with lumen filled with an exudates of mucus
and epithelial cells (D) An airways with severe inflammation and the lumen has been
almost completely obstructed by deposition in the peribronchiolar space (E) Histological
slide from a healthy subject showing lack of emphysema (F) Moderate degree of
emphysema (G) Severe emphysema sample
Images reproduced with permission from Hogg et al.4 and Woods et al.5
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1.3.2

Asthma
Asthma is predominantly a disease of the airways, characterized by sporadic

episodes of strong airway smooth muscle contractions leading to an increase in airway
resistance. The causes of asthma vary between individuals and include allergies, viral
infections and sensitivity to environmental factors.14

The basic defect in asthma is

chronic inflammation of the airways which makes the airway smooth muscles hyperresponsive and causes them to contract strongly.

The trigger for this hyper-

responsiveness can be a variety of factors including exercise, exposure to cigarette
smoke, pollutants, viruses, allergens and a variety of other substances.14 An asthma
attack starts with an early phase, in which mast cells stimulate both contraction of the
bronchial smooth musculature (broncho-constriction) and secretion of mucus in these
airways.13 Within a few hours, a late phase develops as eosinophils, neutrophils, a certain
type of helper T lymphocytes and basophils accumulate in the bronchi and bronchioles,
where these leukocytes secrete additional inflammatory chemicals that damage the
bronchial mucosa and further increase broncho-constriction and secretion of mucus.13
Until recently, it was considered that broncho-constriction was the primary symptom of
asthma and quick relief is still provided by drugs that either inhibit smooth-muscle
contraction (bronchodilators) or inhibit the parasympathetic stimulation of such
contraction (anticholinesterases).

Recently it has been discovered that asthma is

primarily an inflammatory disease and new treatments using anti-inflammatory drugs
(gluco-corticoids and nonsteroidal anti-inflammatory agents) have been developed.13
These drugs allow much better long term management of disease, leading to fewer
attacks and less damage to the airways. Functionally, asthma can be defined as airway
hyper-responsiveness (AHR) leading to areas of airway inflammation and airway
obstruction (partial or complete). It might be due to abnormal functioning of the airway
smooth muscle (ASM) or an excess of ASM cells. A study by Dunnill and colleagues
showed that the percentage of smooth muscle in the segmental bronchial wall was 11.9%
± 3.36% in severe asthma compared to only 4.6% ± 2.2% in healthy controls.32
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1.4

Established Methods for diagnosis of Obstructive Lung Disease
Currently, the pulmonary function tests provide gold standard measurements of

lung function in obstructive lung disease. These are used by physicians for diagnosis of
various pulmonary conditions as well as in research studies. They are used to measure
lung volumes, bronchial obstruction, gas exchange and lung compliance.33 Pulmonary
function tests are able to identify abnormalities of lung function and can also be used to
rule out the possibility of some respiratory disorders such as COPD. These tests are
routinely used in the diagnosis of asthma and COPD. Spirometry is the most widely used
of these tests.34
1.4.1

Spirometry
Spirometry is used to measure static lung volumes at rest-slow (inspiratory or

expiratory) vital capacity (sVC), forced vital capacity (FVC) and dynamic volumesFEV1.33 The test to measure FEV1 involves measuring airflow and lung volumes during
a forced expiratory maneuver from full inspiration. As shown in Figure 1.6.A a handheld EasyOne spirometer (ndd Medizintechnik AG, Zurich, CH) is used for this test. The
test begins with the subject putting the spirometer in their mouth and making a tight seal
around it with their lips to ensure that there is no leakage of air. They are then instructed
to take a couple of normal (tidal) breaths after which they have to inspire fully.
Following this they are instructed to exhale as fast as possible and keep going until there
is no airflow detected by the spirometer. The volume of gas exhaled by the subject in the
first second of the forced maneuver is known as the FEV1 and the amount of gas exhaled
during the entire maneuver is known as FVC as shown in Figure 1.6.B.
The American Thoracic Society’s guidelines for individual spirograms to be
acceptable are if “they are free from artifacts- cough during first round of exhalation,
glottis closure that influences the measurement, early termination or cut-off, effort that is
not maximally throughout, leakage of air, obstructed mouthpiece, if they have a good
start: extrapolated volume <5% of FVC or 0.15 L, whichever is greater and show
satisfactory exhalation: duration >= 6 s or a plateau in the volume-time curve or if the
subject cannot or should not continue to exhale”.35 After three acceptable spirograms
have been obtained the following conditions have to be met- “the two largest values of
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FVC must be within 0.150 L of each other and the two largest values of FEV1 must be
within 0.150 L of each other”.35

If both the criteria are met, the testing may be

concluded, otherwise testing has to be continued until the conditions are met with a
maximum of eight tests performed.35

Although the equipment required to perform

spirometry is simple and robust, the proper performance of the breathing maneuvers and
full cooperation of the patient is critical for getting accurate results. The consistency of
the spirometer and the technician conducting the test is essential because large variations
can be introduced in the results otherwise. The measurements obtained are highly patient
effort dependent and hence the reproducibility of the results might not always be high.
These pulmonary function tests (PFT) are also unable to give any regional information
about the disease and are insensitive to early pulmonary changes after the onset of
disease.
The spirometric measurements of FEV1 and FVC are used to diagnose diseases
like COPD and asthma. The ratio of FEV1/FVC is used to measure airflow obstruction
and a ratio of FEV1/FVC < 0.7 post bronchodilator confirms the diagnosis of persistent
airflow limitation and hence COPD.21 As shown in Table 1.2, COPD is classified into
stages according to the (GOLD) criteria.36
Table 1.2 Classification of COPD according to severity of airflow obstruction.
Adapted from the Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease (Revised 2011), Global Initiative for Chronic
Lung Disease36
Severity

GOLD Stage

Post-Bronchodilator FEV1 Criteria

Mild

GOLD Stage I

FEV1 ≥ 80% predicted

Moderate

GOLD Stage II

50% ≤ FEV1 < 80% predicted

Severe

GOLD Stage III

30% ≤ FEV1 < 50% predicted

Very Severe

GOLD Stage IV

FEV1 < 30% predicted

Specific spirometric cut-off points (e.g., FEV1/FVC < 0.7, FEV1 < 80, 50, 30 %
predicted) are used for simplicity, but have not been clinically validated.36 These fixed
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ratios may result in over-diagnosis of COPD in the elderly, especially in those with mild
disease because the process of ageing does affect lung volumes.36 The predicted values
are calculated depending on age, sex, height, weight and ethnicity as well as the research
study.
Spirometry is also used in the diagnosis of asthma.19 The two main measurements
used are FEV1 and FVC and the ratio of FEV1/FVC is often used by respirologists to
assess lung function.
1.4.2

Plethysmography
A full body MedGraphics’ Elite Series stand-alone body plethysmograph

(MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, MN USA), as shown in
Figure 1.6.C, is a device used to measure lung volumes. The various lung volumes are
shown in Figure 1.7 and their definitions are as follows- tidal volume (TV) is the amount
of air inhaled or exhaled in one breath during relaxed, quiet breathing (typical value in an
average young adult male-500ml), inspiratory reserve volume (IRV) is the amount of air
in excess of tidal inspiration that can be inhaled with maximum effort (typical value in an
average young adult male-3000ml), expiratory reserve volume (ERV) is the amount of air
in excess of tidal inspiration that can be exhaled with maximum effort (typical value in an
average young adult male-1200ml), residual volume (RV) is the amount of air remaining
in the lungs after maximum expiration; keeps alveoli inflated between breaths and mixes
with fresh air on next inspiration (typical value in an average young adult male-1200ml),
vital capacity (VC) is the amount of air that can be exhaled with maximum effort after
maximum inspiration (VC= ERV+TV+IRV); used to assess strength of thoracic muscles
as well as pulmonary function (typical value in an average young adult male-4700ml),
inspiratory capacity (IC) is the maximum amount of air that can be inhaled after a normal
tidal expiration (IC= TV+IRV, typical value in an average young adult male-3500ml),
functional residual capacity (FRC) is the amount of air remaining in the lungs after a
normal tidal expiration (FRC= RV+ERV, typical value in an average young adult male2400ml), total lung capacity (TLC) is the maximum amount of air the lungs can contain
(TLC= RV+VC, typical value in an average young adult male-5900ml).14
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Figure 1.6 Spirometry and Plethysmography
(A) A hand-held spirometer (B) A sample airflow curve obtained from the spirometer
used to calculate FEV1 and FVC (C) A whole body plethysmograph

Measurement of lung volumes requires a method of estimating the volume of gas
inside the thorax. The body plethysmograph uses the small fluctuations in pressure inside
a sealed box containing the patient during breathing to calculate the volume of gas in the
thorax.37 The basic principle behind the body box is Boyle’s law (shown in equation 2,
which states that for a given mass of gas, the product of pressure and volume remains
constant provided that the temperature does not changeP1 x V1 = P2 x V2

(2)

20

Where P1 and V1 are the pressure and volume of gas and P2 and V2 are the pressure and
volume of the same mass of gas after a change in pressure and volume.37 To measure
lung volumes, the patient sits inside a sealed body box. Inside the box there are two
masses of gas: one in the thorax and one outside the body but inside the chamber. The
patient breaths through a mouthpiece with a shutter and performs a series of “pants”
(shallow rapid breathing).

During these “pants” the stutter closes but the subject

continues to pant against the closed shutter. The fluctuations in the box pressure are
measured and the volume fluctuations are calculated. At the same time a pressure
transducer inside the mouthpiece records the pressure changes within the mouth which
can be used as a surrogate for pressure changes inside the lungs. Using these values and
Boyle’s law, FRC can be calculated. Measuring airflow through the mouthpiece during
tidal breathing, maximum inspiration and maximum expiration allows us to calculate all
the other lung volumes.

Figure 1.7 Sample airflow curves obtained through a plethysmograph
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The body plethysmograph attached to a Medgraphics gas analyzer (MedGraphics
Corporation. 350 Oak Grove Parkway St. Paul, MN USA) is also used to measure the
diffusing capacity of the lung for carbon monoxide (DLCO) which is a surrogate
measurement for diffusion of oxygen across the alveolar membrane into the blood.
Carbon monoxide (CO) has similar physical properties as oxygen in terms of its
solubility and ability to diffuse across membranes. It also has the added advantage of
being very strongly bound to hemoglobin, so that the entire CO transferred across the
alveolar wall is retained within the blood and is not exhaled. DLCO is measured by first
instructing the subject to exhale to RV and then inhaling to TLC. During this inhalation
the subject inhales a known concentration of CO (0.3%) and helium (10%) with air.38
After that the subject holds their breath for 8 seconds before exhalation which gives
enough time for the CO to diffuse across the alveolar membrane. The volume of gas is
then collected and analyzed. The exhaled concentrations of CO and helium are compared
to the inhaled concentrations and after correcting for anatomical dead space, the amount
of CO diffusing across the alveolar membrane is calculated. There should be at least two
acceptable tests that meet the repeatability criteria of either being within 3 mL CO
(STPD). min-1.mmHg-1 (or 1 mmol.min-1.kPa-1) of each other or within 10% of the
highest value.38 The average of at least two acceptable tests that meet this repeatability
requirement should be reported. Pulmonary conditions such as emphysema reduce the
surface area to volume ratio of the alveoli and hence the DLCO reported in subjects
suffering from emphysema is often found to be lower than healthy subjects.
1.4.3

Six minute Walk Test
The six minute walk test (6MWT) is safe and easy to administer walk test, and is

well tolerated and better reflects activities of daily living than other walk tests (example
the shuttle walk test).39 The 6MWT is a self-paced exercise test that measures the total
distance the subject can walk on a flat surface in 6 minutes. In severe COPD subjects,
the 6MWT has been shown to be a better predictor of mortality than traditional markers
(FEV1 and Body Mass Index) of disease severity.40
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1.4.4

St. George’s Respiratory Questionnaire
The St George’s Respiratory Questionnaire (SGRQ) is a well established, self-

reported health status questionnaire developed for COPD and asthma.41

The

questionnaire contains three component scores: symptoms, activity and impact on daily
life and a total score.42 The total score goes from 0 to 100 and higher scores indicate
more severe limitation. In both asthma and COPD, SGRQ has been shown to be a valid
measure of impaired health in chronic airflow limitation and is repeatable and sensitive.43

1.5

Pulmonary Imaging
There have been tremendous improvements in pulmonary imaging techniques

during the last two decades. The advancement of imaging methods has improved our
ability to diagnose, characterize and quantify pulmonary pathology.

These imaging

methods provide a noninvasive method of acquiring functional as well as structural
pulmonary information. The technological improvements in computed tomography (CT)
and magnetic resonance imaging (MRI) have led to the development of new techniques
for pulmonary imaging, and recent advancements in nuclear medicine techniques such as
positron emission tomography (PET) have made noninvasive characterization of lesions
possible.44 New methods of pulmonary imaging using CT and MRI have been used to
evaluate pulmonary ventilation and perfusion and to detect small airways disease.44
There has been developmental progress made towards transitioning to digital chest
radiography, which is starting to replace more traditional methods of acquisition,
transmission and viewing of chest radiographs.
1.5.1

Chest X-Ray
X-rays are a form of electromagnetic radiation and on account of their high

frequency and energy are able to pass through a patient’s body and on a X-ray film thus
producing an image.45

While passing through a patient’s body, the X-ray beam is

attenuated by a varying magnitude by different organs depending on the density and
atomic number of the tissue. X-rays turn the X-ray film black, and hence the less dense
the material, the more X-rays get through and the darker the film. Hence, materials of
low density appear darker than objects of high density on the X-ray film. Chest X-rays
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are usually the first imaging method used for pulmonary disease diagnosis because they
are inexpensive,
expensive, widely ava
available, have a relatively low radiation dose46 and allow for
visualization of pulmonary structures like the trachea, carina and major bronchi,
mediastinum and hilar regions and the diaphragm aas shown in Figure 1.8.
1.
The most
commonly used X-ray techniques for the assessment of the lung are the posterior to
anterior (PA) and lateral views taken at TLC.46,47 During these scans the scapula should
be rotated anteriorly, so that they are project away from the lungs and are out of the field
of view (FOV). During a PA scan, the patient stands with their anterior chest wall up
against the X-ray film. The X
X-ray
ray tube lies behind the patient so that the X-rays
X
pass in
the PA direction. In the lateral view, the patient is positioned with their side up against
the film with their arms over their heads so that the scapula is out of the FOV.
FOV On
account of the differencess in density of the various tissues in the thorax, all the structures
appear as different signal intensities
intensities. The bone tissue which is dense and attenuates XX
rays much more thann the lung tissue appears bright whereas the lungs appear dark
because the attenuation caused by the lungs is minimal
minimal.

Figure 1.8 Chest X-Ray
Ray of a 63 year old male COPD Stage III subject
(A) P-A view (B) Lateral View. Adapted from Parraga et. al (2007).3
The average dose from a chest X
X-ray
ray (single PA film) is 0.02 mSv.46 The average
natural environmental background radiation is approximately 0.01 mSv/day,48 although
there are places on earth that have values that are 55-tmes higher.49 Considering the
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average environmental exposure of 0.01 mSv/day, the average dose from a PA chest Xray is equivalent to that a person receives from the environment in about 2 days. Ionizing
radiation, such as X-rays, is capable of creating ions by knocking electrons out of their
orbits. When biological molecules are exposed to X-rays, these X-rays interact with the
water molecules within the body leading to the formation of hydroxyl radicals. These
radicals then interact with the nearby Deoxyribonucleic acid (DNA) to cause strand
breaks or base damage. X-rays are also capable of ionizing DNA directly. While
radiation-induced damage is repaired within the cell, DNA double-strand breaks are more
difficult to repair and occasional misrepair can lead to induction of point mutations,
chromosomal translocations and gene fusion which are all linked to cancer induction.50
Therefore, the low radiation dose, along with quick acquisition time, is a very important
advantage of a chest X-rays compared to CT. Various lung structure abnormalities can
be identified using a chest X-ray such as flattening and increased translucency of the
diaphragm which is commonly associated with gas trapping in respiratory disease.
However, in a chest X-ray, all the anatomical structures are super-imposed on top of one
another making it difficult to diagnose diseases like COPD, particularly in early disease
stages. Hence chest X-rays are used for assessment of more advanced morphological
lung changes in COPD.51
1.5.2

X-ray Computed Tomography
X-ray CT is another major imaging modality used in the evaluation of pulmonary

disease.

Traditionally, CT images are a two-dimensional representation of a cross-

sectional slice through a region of interest in the body.47 The third dimension of the
image is the slice thickness which could range from 1 to 10mm.47 These cross-sectional
images are obtained by using X-rays being emitted by an X-ray tube on one side of the
gantry with a set of detectors on the other. The patient passes through the gantry that
rotates around at the level of interest. Information from the detectors is analyzed by
computers and displayed as an image. Owing to the use of computer algorithms, a much
greater array of densities can be displayed compared to conventional X-ray films. This
allows for differentiation of solid organs from each other and from pathological processes
such as tumors and fluid collection. It also makes this imaging modality extremely
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sensitive to the presence of minute amounts of fat, calcium or contrast material. As with
a chest X-ray, high density objects attenuate the X-rays to a higher magnitude and
therefore appear as lighter gray than objects of lower density, which appear darker.45
White or light gray objects are therefore called ‘high attenuation’ whereas dark grey and
black objects are called as ‘low attenuation’. In a CT scan, image information can be
manipulated to highlight the organ of the body being studied. This is called ‘altering the
window setting’.45 For example, in a chest CT where a wide range of tissue densities are
present, a good image of the mediastinal structures shows no lung details. However, the
lung parenchyma can be observed in full detail by setting a lung window.
The CT image is composed of multiple pixels and images are usually 512 pixels
by 512 pixels. The pixel area multiplied by the slice thickness defines the voxel volume.
The X-ray attenuation of the structures within a voxel is averaged to produce the
attenuation value for the voxel that is recorded to produce an image. Each voxel in a CT
image is assigned a Hounsfield unit (HU)52 based on its attenuation coefficient relative to
that of distilled water at room temperature as shown in equation (3).

 

 


1000

(3)

where µ x is the linear attenuation coefficient of the object and µ water is the linear
attenuation coefficient of water. Based on this, water is assigned a value of 0 HU, while
air has a value of -1000 HU and all the tissues with an attenuation coefficient higher than
that of water (materials denser than water) are assigned positive HU values.53
Standardization of the units allows for direct comparison between scans acquired on
different scanners made by different manufactures.
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Emphysema is pathologically defined as the presence of permanent enlargement
of air spaces and therefore these air filled regions have HU values closer to that of air
than healthy tissue and appear dark in CT scans as shown in Figure 1.9
9. There are two
basic patterns of emphysema that ca
can
n be identified: centrilobular and panlobular.
Centrilobular emphysema is typically more pronounced within the upper lobes and in CT
images shows up as regions of decreased attenuation, without definable walls that are
confined to the center of the secondary lobule.47 The changes in lung structure associated
with panlobular emphysema ar
are predominantly observed in the mid and lower lungs.
lungs On
CT images, it is characterized by large regions of low attenuation leading to an apparent
simplification
ification of lung architecture.47 Emphysema
ema can also be quantitatively measured
using CT images by using a HU threshold to quantify the volume of the lung below the
threshold.

Figure 1.9 X-ray
ray computed tomography (CT)
(A) CT center slice from a 55 year old male healthy smoker (B) CT center slice from a
60 year old female COPD stage 2 subject
he biggest disadvantage of CT is related to its use of high doses of ionizing
The
radiation, hazards of intravenous contrast, lack of portability of equipment and its
relatively high cost. An average abdominal CT scan has a dose of 10 mSv, which is
equivalent to 500 chest X
X-rays
rays or the equivalent to 3 years of background radiation.46 In
COPD, there is a need for following the patients serially over years for evaluating disease
progression and response to treatment which means getting regular CT scans and
a
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exposing the patients to high levels of ionizing radiation. There is a lot of concern about
exposing the patients to high amounts of ionizing radiation since there is an increased risk
of radiation-induced cancer from cumulative dose related to repeat CT scans.54
Assessment of emphysema using CT scans also has certain other limitations like low
specificity, low sensitivity in the evaluation of mild disease and considerable interobserver variability in the interpretation of the findings.55
1.5.3

Nuclear Medicine
Nuclear medicine involves the administration of small amounts of compounds

labeled with radioactivity (radionuclides) that are used to provide diagnostic information
in a wide range of diseases. It involves injecting a compound into the body which is
labeled with a gamma-ray-emitting or positron-emitting radionuclide. The radio labeled
compound is called a radio-pharmaceutical, or more commonly as tracer or radiotracer.
When the radionuclide decays, it emits gamma rays or high-energy photons. These
gamma rays or photons have sufficient energy so that they can exit the body without
being scattered or attenuated.56 Gamma cameras are attached around the bore of the
scanner which can detect these rays or photons and form an image of the distribution of
the radionuclide.56 There are two main classes of nuclear medicine imaging: single
photon imaging [which includes scintigraphy and single photon emission computed
tomography (SPECT)] and positron imaging [positron emission tomography (PET)].
Scintigraphy uses radionuclides and gamma cameras to form two-dimensional
images and can be thought of as being the nuclear medicine equivalent of a chest X-ray.
Lung ventilation scintigraphy can be performed using radioactive gases57 or labeled
aerosols58. The radioactive gases most commonly used for lung scintigraphy are xenon
and krypton (133Xe,127Xe and

81m

Kr).57

The images formed are a two-dimensional

projection of the organ being studied. Although planar scintigraphy imaging is still
commonly used to study pulmonary ventilation and perfusion, the introduction of the
more advanced three-dimensional SPECT about 20 years ago made scintigraphy obsolete
in several fields.
SPECT is similar to scintigraphy and can be thought of the CT equivalent of
nuclear medicine. Multiple projections (scintigraphs) are acquired at different gamma
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camera positions and all the images are reconstructed into a volume which can then be
analyzed on a slice by slice basis.

This enables cross-sectional images to be

reconstructed, providing the depth information missing from planar scintigraphy. Some
of the radioactive isotopes used for SPECT are

133

127

Xe,

Xe,

81m

Kr and a particular

aerosol: Technegas, which is called as “pseudo-gas” because of its very small particle
size, giving it properties similar to that of a gas.59,60 SPECT can be used to analyze
ventilation and perfusion in the lungs. Matching of ventilation and perfusion is critical
for efficient gas exchange and therefore oxygen supply to the tissue.61 Ventilation can be
studied using various tracer gases like

133

Xe or technetium 99m (99mTc).62,63 Evaluation

of wash-in, breath-hold and wash-out phases using a tracer gas can help in detection of
functional abnormalities in lung volumes and study ventilation patterns, thus making it
sensitive to gas trapping and areas of high resistance within the bronchial tree.62,63
It is critical to study the perfusion pattern along with the ventilation pattern
because without perfusion, gas exchange cannot happen even if there is perfect
ventilation. The most common radiopharmaceuticals used for perfusion lung imaging are
99m

Tc labeled macro-aggregated albumin (MAA).47 Prior to the scan the radio-labeled

particles of MAA, marked with

99m

Tc are injected into the peripheral vein.57 These

particles are 15-100 µm in size and get lodged in the pulmonary capillaries and precapillary arterioles as they move along in the blood stream. The particle distribution
accurately illustrates regional perfusion.

It is critical to account for the number of

particles given to the patient. A minimum of 60000 particles are required to obtain an
even distribution of activity reflecting regional perfusion.64 Normally, about 400,000
labeled particles are injected.57

Bearing in mind that there are over 280 billion

pulmonary capillaries and 300 million pre-capillary arterioles, the routinely administered
particles will result in the blockage of only a small fraction of pulmonary vessels.57
MAA is eventually broken down by the body and the obstruction in the arterioles will be
removed and normal blood supply will resume. Since

99m

Tc is radioactive,65 a radiation

dose is given to the subject with each SPECT scan. A ventilation scan with 99mTc has an
effective dose between 0.1 - 0.6 mSv, depending on the protocol and a perfusion scan has
an effective dose of 1.0 mSv.66 A single gamma ray is emitted when each of the isotopes
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used in the scan undergoes decay which is then detected by the gamma camera and the
image is reconstructed.
Similar to SPECT imaging, positron emission tomography (PET) images contain
structural and functional information of an organ acquired from decaying nucleotides by
emission of photons. PET involves the administration of a radioisotope that decays by
emitting a positron. The positron annihilates with an electron producing two 511-keV
anti parallel photons.57 The two photons have to travel 180 degrees from each other in
order to conserve momentum.67 Radionucleotides used in PET imaging are 11C, 13N, 15O,
18

F,

19

Ne and

68

Ga.68 Fluorodeoxyglucose ([18F] FDG) is the most widely used PET

tracer in clinical practice as it has the longest half life (110 minutes) among all the
elements used for PET.68 During a scan the patient lies in a supine position in the bore of
the scanner which is completely surrounded by gamma cameras. When an annihilation
event happens, the emitted photons travel in opposite directions and strike the gamma
cameras at the opposite side of the bore. There is usually a difference in the arrival times
of these two photons as the distance they have to travel to get to the cameras is not
identical, unless the annihilation happens exactly at the bore of the scanner.

The

difference in arrival times of anti-parallel photons is used to localize the position of the
annihilation and spatially identify the areas of annihilation.67

Based on all the

annihilation data, a computer algorithm can construct the PET image.
1.5.4

Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is a powerful, noninvasive imaging modality

that has experienced rapid growth over the last 10-15 years. MRI does not use ionizing
radiation to produce images and hence does not give a radiation dose to the patients like
CT, SPECT or PET. MRI is based on the fact that when hydrogen nuclei are placed in a
magnetic field and stimulated by radio waves of a particular frequency, they emit some of
the absorbed energy in the form of radio signals. These signals can be used to create an
image.69 The advantages of MRI compared to CT are the lack of ionizing radiation;
increased soft tissue contrast; the ability to directly image in coronal, sagittal or oblique
planes as well as the transverse plane and the intrinsic contrast in the blood vessels as a
result of flow phenomenon.
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Pulmonary imaging using Conventional Proton (1H) MRI
The lung is the most difficult organ to image using the conventional 1H MRI.70,71
Problems associated with lung imaging include intrinsically low hydrogen proton density
within the lung, local field inhomogeneities and cardiac and respiratory motion.72
Approximately 70% of the healthy lung is filled with air, which has minimal hydrogen
proton density, making it extremely difficult to acquire any structural and function
information using conventional proton MRI.72

On account of the vastly different

properties between air and tissue, the countless interfaces between air and tissue generate
susceptibility artifacts that result in a loss of signal of fine structures such as alveolar
septae.72 Magnetic susceptibility is the measure of the strength of the magnetic field that
the external magnetic field creates in a material. Susceptibility artifacts occur as a result
of microscopic gradients or variations in magnetic field strength that occur near the
interface of substances of different magnetic susceptibility such as air and tissue. The
result is the formation of bright and dark areas with spatial distortion of surrounding
anatomy. Cardiac and respiratory motion also causes motion artifacts in the images due
to the relatively large image acquisition time.70 The motion artifacts in the images can be
minimized by acquiring the MRI under breath-hold conditions, although this means
severe constrains on the duration of image acquisition.

Figure 1-10 shows a

conventional proton MRI center slice of the lung. As can be observed, the lungs appear
as two “black holes” on the MRI which makes it difficult to extract functional or
structural information about lung anatomy from the images. However, recently there
have been developments that have led to the mitigation of these problems.
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Figure 1.10 Conventional proton MRI of the lung
Pulse sequence used is fast spoiled gradient
gradient-recalled-echo sequence with a 40cm x 40cm
FOV
Some of the new techniques developed recently are ultra
ultra-short
short echo time (UTE)
MRI,73-75 oxygen-enhanced
enhanced MRI

28,76

and Fourier decomposition methods77. In human

subjects, ultrashort echo delay ((TE) gradient-echo
echo sequence has been shown to increase
the lung parenchyma signal intensity.78 The problem with conventional MRI is that due
to the large magnetic
etic field inhomogeneities, the apparent transverse relaxation time T2*
is very short which makes conventional echo
echo-based
based pulse sequences inadequate for
acquiring signal from the lung parenchyma.79 The amount of signal acquired after the TE
with conventional gradient
gradient-echo (TE=15 msec) or spin-echo
echo (TE= 20 msec) sequences is
minimal after the conventional MR
MRI systems begin to operate in receive
rec
mode.73
However this problem can be overcome with faster pulse sequences like UTE.
UTE It has
been shown that lung MRI images with diagnostic quality comparable to that of CT can
be acquired in cystic fibrosis (CF) patients using short TE pulse sequences.80 Pulse
sequences that employ shorter TE generally give higher signal intensity as compared with
conventional pulse sequences that use longer TE
TE. In oxygen-enhanced
enhanced MRI, inhaled
molecular oxygen is used as a contrast agent for visualizing the transfer of oxygen across
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the alveolus into the pulmonary vasculature. Initial studies with oxygen enhanced MRI
in patients with emphysema showed ventilation defects corresponding to bullous changes
in the lungs.28 This method has been able to show significant differences between
subjects with and without emphysema and has an excellent correlation with FEV1 and
DLCO.28,81

Oxygen-enhanced MRI has been able to show differences in regional

ventilation in human subjects. Fourier decomposition in proton MRI is another imaging
method that has been used for non-contrast-enhanced regional lung perfusion and
ventilation studies.77 It has also been shown that there is qualitative agreement in the
assessment of regional lung ventilation and perfusion between Fourier decomposition
proton MR imaging and conventional SPECT/CT in an animal model.82 High resolution
ventilation distribution maps have been characterized with this method.83 All these
methods have undergone rapid development in the past few years and hold promise in the
future.

Another method that has been extensively used to study the structural and

functional pulmonary pathology has been hyperpolarized noble gas MRI.
Hyperpolarized Noble Gas MRI
Hyperpolarized noble gas MRI had been used over the last 2 decades to study
lung structure and function. This method was first developed by Albert and colleagues in
1994.84 In conventional MRI, the signal intensity of the image depends on the total
magnetization in the chosen sample volume element. When a sample containing protons
is kept in an external magnetic field, all the protons like up either in the parallel or the
anti-parallel direction to the magnetic field. The number of protons lined up with the
field is slightly higher than that of protons lines up against the field. The ratio of the
number of protons lines up with the field to that of the number of protons liked up against
the field is called the polarization and in large magnetic fields, thermal-equilibrium
polarizations reach close to 10-5 meaning that the probability of excess spins being
aligned with the field is about 1 in 100000. But with the massive number of protons in
the human body, even this minute probability is enough to get good quality images.
However, for inhaled contrast agents, the concentration is not enough to be used in
conventional high-speed, high-resolution MR scanners.84 In hyperpolarized noble gases,
the polarization is boosted before the patient inhales the gas in a process known as
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hyperpolarization. This process allows for better signal from the inhaled contrast agent
and gives better quality images by increasing the polarization of the gas by four to five
orders of magnitude.85 The polarization of

129

Xe and other spin ½ noble gases can be

enormously enhanced through a process known as spin-exchange with an optically
pumped alkali metal vapour such as rubidium (Rb). During optically pumping, circularly
polarized laser light is directed into a glass cell containing a vapour of Rb and the noble
gas. This causes a transfer of angular momentum form the light to the electrons of the Rb
and the Rb atoms are said to be polarized. When these Rb atoms collide with the noble
gas atoms, there is a transfer of angular momentum form the Rb to the noble gas. The
transfer of angular momentum happens from the electron spins of the Rb to the nuclear
spins of the noble gas. The wavelength of light required to polarize the electrons in Rb
and get the hyperpolarization process started is 794.8 nm.85
experiments in hyperpolarized gas MRI were done using

129

Although the first

Xe gas,84 3He has been the

contrast agent of choice since then due to the nearly 3-fold gyromagnetic ratio of 3He
(3He:32.4MHz/T,129Xe: 11.8 MHz/T)86 and higher enrichment, both of which lead better
signal with 3He than 129Xe.
Hyperpolarized 3He MRI has been used to study the structural and functional
changes in diseases like COPD,3,5,87-91 asthma,92-100, CF101-103 and radiation induced lung
injury (RILI),104,105 lung cancer106 and lung transplant107-109. The main application of
hyperpolarized noble gas lung imaging is to study the structural and functional features of
the lung, quantify these measurements and monitor the changes longitudinally. The two
main measurements used for these applications are ventilation defect percent (VDP)110,111
and apparent diffusion coefficient (ADC)3,98,112. Figure 1.11 shows hyperpolarized 3He
MRI images for a healthy volunteer (A), subject with COPD (B), asthma (C) and CF (D).
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Figure 1.11 Hyperpolarized 3He MRI images
(A) 26 year old female healthy volunteer with FEV1%pred = 92 and FEV1/FVC = 91
(B) 77 year old female stage 3 COPD subject with FEV1%pred = 50 and FEV1/FVC = 50
(C) 50 year old female asthma subject with FEV1%pred = 71 and FEV1/FVC = 68
(D) 38 year old male CF subject with FEV1%pred = 49 and FEV1/FVC = 55
The yellow arrows indicate regions of abnormal ventilation called ventilation defects
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Ventilation defect percent (VDP) is the measurement of the percentage of the lung
that is not being ventilated. “Defects” in the lungs are the areas of the lungs that appear
dark in a hyperpolarized noble gas MRI and represent regions of the lungs that are hypoventilated or not ventilated at all. These regions have been highlighted using arrows in
Figure 1.11. The earliest pulmonary imaging study using 3He MRI studied a single
healthy volunteer and showed that 3He MRI images were able to show a sharp
demarcation of the lungs against the diaphragm, heart, chest wall and blood vessels
which do not give any signal.113 This study also showed that the signal intensity within
the air spaces was proportional to the concentration of the 3He gas and hence proportional
to the actual ventilation within that region of the lungs.113 Bachert et al. showed that the
signal distribution in a healthy volunteer was highly homogeneous within the lungs with
a signal void for vascular and cardiac structures.114 This study also suggested that 3He
MRI could be a viable alternative to the established methods for pulmonary imaging all
of with used ionizing radiation.114 The first multi-subject study using 3He MRI was
performed by Kauczor et al. who studied static ventilation images obtained using 3He
MRI in healthy volunteers as well as subjects with pulmonary diseases.115 Kauczor et al.
observed that there was homogeneous signal intensity over the lungs and hence uniform
ventilation for the healthy volunteers. In subjects with COPD and other lung conditions,
they found that the signal intensity was highly heterogeneous with the presence of large
wedge-shaped “ventilation defects”. This study demonstrated that it was possible to
distinguish between healthy subjects and patients suffering from pulmonary diseases
using hyperpolarized noble gas MRI. Subsequently there were studies that found good
correlation between ventilation defects observed with hyperpolarized 3He and xenon-133
scintigraphy.116,117 Studies have also shown good correlation between ventilation defect
scores assessed using 3He MRI and 81mKr scintigraphy for a group of healthy subjects and
COPD patients.118 The defect scores calculated using 3He MRI were also found to be
well correlated with high resolution computed tomography (HRCT) and pulmonary
function tests.118

3

He MRI was shown to be more sensitive than CT at detecting

ventilation defects in lung transplant candidates.119 For CF patients, McMahon et al.
found a strong correlation between 3He MRI and HRCT measurements and between 3He
MRI measurements and FEV1 and FVC.120

36

Other studies have also found a good correlation between 3He MRI measurements
and the gold standard for pulmonary imaging- CT as well as 3He MRI measurements and
spirometry.91,121,122 The safety profile of hyperpolarized 3He gas has also been studied
and found to be safe for administration to healthy subjects, heavy smokers and those with
obstructive lung disease.117,123,124
Mathew et al. studied the reproducibility of hyperpolarized 3He measurements in
healthy volunteers and COPD subjects and found the ADC reproducibility to be high for
same day as well as 7-day rescan.125 Same-day reproducibility for ventilation defect
volume (VDV) was also found to be high, and 7-day reproducibility for VDV was
moderate.125 Niles et al.

studied the reproducibility of 3He MRI measurements in

subjects with exercise induced bronchoconstriction and found that inter-day and interreader reproducibility was generally high when using the same method for image analysis
at the two sites involved in the study.97 Parraga et al. studied the reproducibility of
ventilation defects in healthy elderly subjects and found that there was high
reproducibility for same day re-scan and moderate to high reproducibility for 7-day
rescan.126 Diaz et al. studied the reproducibility of 3He MRI ADC measurements in
healthy volunteers and patients with emphysema for three visits over 7 days.127 They
reported high reproducibility in ADC measurements for healthy subjects as well as
patients with emphysema over the three visits.127

Parraga et al. studied the

reproducibility of 3He MRI ADC and ventilation defect measurements in healthy
volunteers and COPD patients scanned three times, twice within 10 minutes and again 7
± 2 days later and reported excellent same-day and 7-day ADC reproducibility as well as
excellent reproducibility for same-day ventilation defect scoring and ventilation defect
volume (VDV).3 Hence, hyperpolarized 3He MRI has been shown to be a safe, noninvasive and reproducible method for studying lung structure and function and has the
added advantage that it does not use ionizing radiation. However, there are certain
problems with 3He MRI that has made its clinical transition virtually impossible, at least
with the technology that is available at this moment.
During the last decade or so the demand for 3He gas has gone up tremendously
and its cost has skyrocketed. The cost of 1 liter of 3He gas has gone up from $100 a
couple of years ago to more than $2100 according to a recent report.128 There has been a
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very high demand for 3He gas from the US Department of Homeland Security (DHS) and
Department of Energy (DOE) which has led to the US inventory of 3He plunging from
200,000 liters in 2001 to somewhere between 43,000 – 48,000 in 2010.128

DOE

3

anticipates that it will have less than 8000 liters per year of He to sell for the next few
years while the demand is expected to rise from the 76000 liters in 2009.128 In the wake
of the 9/11 terrorist attacks, the DHS initiated a program to install more than 1400
radiation monitors at ports and border crossings which need 3He gas to function.129 This
huge demand came at the same time that there was a dip in supply of 3He due to a
reduction of nuclear weapons production.129

3

He gas is produced when tritium (used to

boost the yield of nuclear weapons) decays and when there was a reduction in nuclear
weapons production, naturally there was a dip in tritium decay and hence production of
3

He.129 By early 2009, the total demand for 3He in the United States was over 213,000

liters and the supply was 45,000 liters.129

Although theoretically tritium could be

manufactured in commercial reactors to help meet the 3He demand, the cost would be
enormous- more than $20,000 per liter by one estimate and would take more than 20
years to yield sufficient quantities of 3He.128

The increasing price and the lack of

availability of 3He has forced the hyperpolarized noble gas pulmonary imaging field to
look for alternatives to 3He as a contrast agent and 129Xe has emerged as a good prospect.
129

Xe is much more abundant as compared to 3He and is much cheaper as well.

After the first study of hyperpolarized noble gas pulmonary imaging was reported using
129

Xe,84 the field transitioned to using 3He as a contrast agent as it had a simpler and more

mature polarization technology,85 a larger magnetic moment and absence of physiological
effects.130 However, recently there has been a resurgence in 129Xe MRI research leading
to development of methods to improve the volume of polarized gas required for research
and clinical studies as well as the polarization of the gas itself.130-134 Xenon has had a
long history of being a safe contrast agent in CT studies.135 The safety profile of

129

Xe

MRI has also been studied and found to be safe in healthy volunteers as well as
obstructive and restrictive pulmonary disease subjects.130,136 Recently there have been
studies

undertaken

measurements.137-139

to

compare

3

He

MRI

measurements

with

129

Xe

MRI

Results have shown that although there are differences in the

physical properties of 3He and 129Xe, 129Xe is potentially an excellent alternative for 3He
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in pulmonary imaging studies.
pulmonary diseases using

129

There have also been other studies to investigate

Xe as a contrast agent.131,140-143 However, there have not

been any studies to investigate the reproducibility of hyperpolarized

129

Xe MRI

measurements over short periods of time.
Studying the reproducibility of

129

Xe measurements over short periods of time is

critical in clinical study design. For example, in longitudinal clinical studies that aim to
use

129

Xe MRI measurements of disease, it will be critical to understand variability that

can be attributed to 1) image acquisition methods, including those related to the scanner
(field strength, coils used) and subject compliance (breath-hold, motion), 2) image
analysis methods that are observer-dependent or computationally driven, 3) site specific
methodologies including hyperpolarization of the gas and the gas delivery methods, 4)
potential physiological and radiological changes that occur over short periods of time. In
order to be confident about the physiological differences being observed in pulmonary
diseases, we first have to be confident about the reproducibility of the measurement being
used to study these physiological changes.
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Figure 1.12 Hyperpolarized 129Xe MRI images
(A) 26 year old female healthy volunteer with FEV1%pred = 92 and FEV1/FVC = 91
(B) 77 year old female stage 3 COPD subject with FEV1%pred = 50 and FEV1/FVC = 50
(C) 50 year old female asthma subject with FEV1%pred = 71 and FEV1/FVC = 68
(D) 38 year old male CF subject with FEV1%pred = 49 and FEV1/FVC = 55
The yellow arrows indicate regions of abnormal ventilation called ventilation defects
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Figure 1.13 Hyperpolarized 129Xe ADC maps
(A) 26 year old female healthy volunteer with FEV1%pred = 92 and FEV1/FVC = 91
(B) 77 year old female stage 3 COPD subject with FEV1%pred = 50 and FEV1/FVC = 50
(C) 50 year old female asthma subject with FEV1%pred = 71 and FEV1/FVC = 68
(D) 38 year old male CF subject with FEV1%pred = 49 and FEV1/FVC = 55
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1.6

Thesis Hypotheses and Objectives
Hyperpolarized noble gas lung imaging allows us to acquire high temporal and

spatial resolution structural and functional images of healthy volunteers and subjects with
obstructive and restrictive pulmonary diseases. These images allow us to visualize the
ventilation pattern in the lungs and identify regions of no ventilation known as
“ventilation defects”. The lung microstructure can also be studied using the apparent
diffusion coefficient measurement.

Since the first pulmonary images using

hyperpolarized noble gas were acquired in 1994, there have been significant
improvements in the quality of the images acquired. There has also been development of
various measurements to study the structural and functional changes taking place in the
lungs after the onset of disease.

However, while there have been multiple studies

investigating the reproducibility of hyperpolarized 3He MRI measurements; there have
not been any to investigate the reproducibility of

129

Xe measurements.

Hence the

overarching aim of this thesis was to investigate the intra-observer and inter-observer
reproducibility of hyperpolarized

129

Xe MRI measurements. We wanted to study the

reproducibility of the VDP measurement for healthy volunteers and subjects with COPD
for same day rescan and 1-week rescan. We also wanted to investigate the differences
between two-dimensional (2D) and three-dimensional (3D) image acquisition methods
for

129

Xe static ventilation images. We hypothesize that the

129

Xe MRI VDP will be

reproducible for repeated scans over short periods of time when no physiological change
is expected to occur in the lungs. We also hypothesize that there will not be any
differences observed in the measurements obtained from 2D or 3D image acquisition.
Chapter 2 describes the materials and methods used for this study. Chapter 3
outlines the results of the reproducibility analysis and chapter 4 presents the discussion
and conclusion for the work and also includes the study limitations and directions for
future work in the study of the reproducibility of the 129Xe MRI measurements.
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2

CHAPTER 2: MATERIALS AND METHODS
Chapter 2 provides details about the study design and the study subjects. Details

about the pulmonary function tests as well as image acquisition and data analysis
methods are provided to help the reader better understand how the results presented in
chapter 3 were acquired and analyzed.

2.1

Study Subjects
Five healthy volunteers (HV) and ten COPD subjects were enrolled from the

general population and a local tertiary health care center. All subjects provided informed
written consent to the study protocol approved by the local research ethics board and
Health Canada, and the study was compliant with the Personal Information Protection
and Electronics Documents Act (PIPEDA, Canada) and the Health Insurance Portability
and Accountability Act (HIPAA, USA). COPD subjects required a disease diagnosis of
at least 1 year, having had a smoking history of at least 10 pack-years and fewer than
three COPD exacerbations within the previous 12 months.

COPD subjects were

categorized according to the GOLD criteria.1 HV were included if they had no history of
chronic respiratory disease, less than one pack-year smoking history, FEV1 greater than
80% predicted, FEV1 divided by the FVC or FEV1/FVC greater than 70%, and no current
diagnosis or history of unstable cardiovascular disease.
Throughout the course of the study, COPD subjects were withdrawn from the
study if they had experienced a COPD exacerbation or if they experienced a drop in
arterial blood oxygen levels below 80% for 15 continuous seconds during MRI
procedures as monitored using pulse oximetry.

After providing informed written

consent, the subjects underwent physical examination and their vital signs were recorded
followed by spirometry and plethysmography. All subjects were screened for MRI safety
and coil compatibility before the MRI session and at all times during the MR scan, an
expert was present in the MRI suite with the subject to administer the gas to the subject
and coach their breathing maneuvers. The subjects breathed in 1L of gas from FRC to
ensure uniformity in lung volume for all the scans. This was useful in eliminating errors
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in measurements due to differences in lung volume for the same subject due to
differences in the volume of inhaled gas.

2.2

Pulmonary Function Tests
Spirometry

was

performed

using

an

ndd

EasyOne

spirometer

(ndd

Medizintechnik AG, Zurich, CH) (Figure 1.6.A) measuring FEV1 and FVC with a
minimum of three acceptable spirometry maneuvers with the best FEV1 and FVC
selected for analysis according to American Thoracic Society (ATS) guidelines2 (Figure
1.6.B). Whole body plethysmography was performed using a MedGraphics’ Elite Series
stand-alone body plethysmograph (MedGraphics Corporation. 350 Oak Grove Parkway
St. Paul, MN, USA) (Figure 1.6.C) for the measurement of total lung capacity (TLC),
inspiratory capacity (IC), residual volume (RV) and functional residual capacity (FRC).
A body plethysmograph attached to the Medgraphics gas analyzer was used to measure
the DLCO.

2.3

Image Acquisition
129

Xe MRI was performed on a whole body 3.0 Tesla Discovery 750 MR system

(General Electric Health Care (GEHC), Milwaukee WI) with broadband imaging
capability as previously described.3 Hyperpolarized

129

Xe MRI was acquired using a

custom-made, unshielded quadrature-asymmetric bird-cage coil tuned to 35.34MHz, as
previously described.4,5
129

Xe gas (86% enriched) was polarized to 10-60% using a turn-key polarizer

(XeBox-E10, Xemed LLC, New Hampshire, USA). Doses of hyperpolarized

129

Xe gas

were dispensed directly into the pre-rinsed 1.0L Tedlar® bags pre-filled with 4He to
generate a 50/50 mixture of 4He gas and hyperpolarized

129

Xe gas. Polarization of the

diluted dose was measured using a Polarimeter (GEHC, Durham, NC).
During the scanning visits, diffusion-weighted (DW) and non-diffusion-weighted
(NDW) images were acquired during a breath-hold of a 1L

129

Xe/4He mixture inhaled

from FRC. NDW images were obtained using a two-dimensional fast gradient recalled
echo (2D FGRE) sequence with centric phase-encoding ordering as shown in Figure
2.1.A.

Two interleaved images (16s total data acquisition, TE/TR/flip angle = 10
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ms/13.5 ms/9o, bandwidth = 31.25 kHz, FOV = 40 x 40 cm, matrix 128 x 80, 7 slices,
30 mm slice thickness, 0 gap), with and without additional diffusion sensitization (G =
2.90 G/cm, gradient rise and fall time = 0.5 ms, gradient separation = 2 ms, gradient
duration = 2.0 ms, diffusion time = 5 ms) were acquired.
During the same visit, 129Xe MRI coronal static ventilation (SV) images were also
acquired during a breath-hold of a 1L

129

Xe/4He mixture inhaled from FRC (14s data

acquisition, TE/TR/flip angle = 1.50 ms/6.7 ms/1o, bandwidth = 15.63 kHz, FOV = 40 ×
40 cm, matrix 128 × 128, 14 slices, 15 mm slice thickness, 0 gap) using a threedimensional fast gradient recalled echo 3D FGRE sequence as shown in Figure 2.1.B.
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Figure 2.1 FGRE pulse sequences
(A) 2D FGRE, (B) 3D FGRE, Gs = slice select gradient, GØ = phase encode gradient, Gf
= frequency encode gradient, TR= repetition time, TE= echo time. Adapted from
Hornak, J.P, The Basics of MRI 10

The NDW images were used to assess the

129

Xe static ventilation reproducibility

between the repeated scans. The NDW images were acquired at multiple time-points and
hence were used to study the reproducibility of

129

Xe VDP over multiple time-points.

Subjects were instructed to perform normal tidal breathing from room air before inhaling

57

the entire contents of the 1L dose bag mixture from FRC and perform a breath hold of 815 seconds. This training was important to minimize the potential for differences in the
levels of inspired gas between the breath-hold scans for each subject. The entire process
of acquiring the xenon static ventilation images is illustrated in Figure 2.2. The time
frame between

129

Xe scans was within 2 ± 1 minute for all subjects for the same day

rescan and 7 days for the three COPD subjects who returned one week later for another
visit. The 3 subjects who returned for the 1-week rescan had two NDW scans done
within 2 ± 1 minute of each other at the second visit. A 1-week period between scanning
sessions was selected to minimize subject inconvenience and to model typical sources of
variability stemming from the acquisition of the images over a short period of time
because of coil positioning, subject motion and positioning changes and potential shortterm physiological changes. Repeat spirometry at the second MRI visit was performed to
screen for exacerbations or global disease changes that may have occurred during the 1week scanning period.

Figure 2.2 Image acquisition procedure
Subjects were instructed to lay supine in the custom built 129Xe bird cage coil which was
positioned inside the bore of the MRI. The 129Xe gas was hyperpolarized using the
polarizer and images were acquired during a breath-hold after the subjects inhale the
entire contents of the bag.
For all the subjects,

129

Xe gas breath-holds followed standard full inspiration

breath-hold 1H MRI with subjects scanned during a 1L breath-hold of medical grade
nitrogen (N2) (Spectra Gases, Alpha, NJ) using the whole body radiofrequency (RF) coil
and 1H fast spoiled gradient-recalled-echo sequence as previously described.3
Hyperpolarized 3He MRI was enabled using a linear bird-cage transmit/receive
chest coil (RAPID Biomedical GmbH, Wuerzburg Germany).

A turnkey system

(HeliSpin™) was used to polarize 3He gas to 30-40% and doses (5mL/kg body weight)
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were administered in 1.0L Tedlar® bags diluted with N2. Hyperpolarized 3He MRI
coronal SV images and NDW images were acquired during breath-hold of a 1L 3He/N2
mixture as previously described.3 Figure 2.3 shows the sequence in which the scans
were acquired and time-period between the scans.

The time-period between the

consecutive scans acquired on the same day was 2±1 minutes. The time-period between
the two visits was exactly 1-week for all the 3 subjects who returned for the second visit.

Figure 2.3 Sequence of scans acquired
1
H= proton, NDW= non-diffusion-weighted, SV= static ventilation
He= Helium-3, Xe= Xenon-129, PFTs= Pulmonary Function Tests

2.4

Image Analysis
A single expert observer analyzed the

129

Xe NDW and SV as well as the 3He

NDW and SV images for regions of signal void known as ventilation defects using an inhouse software developed using MATLAB R2007b (The Mathworks Inc., Natick, MA,
USA) as previously described.6

The analysis was performed within an image

visualization room with background lighting levels consistent for all image analysis
sessions and the entire analysis was repeated five times (5 rounds) as shown in Figure
2.3. For each round of analysis, the subjects and scans were randomized to minimize the
observer bias in the analysis. A period of two days was left between consecutive rounds
of analysis to minimize the possibility of observer bias between rounds. To study the
inter-observer reproducibility of
repeated

129

129

Xe MRI VDP, a second observer analyzed the

Xe NDW and SV images once (1 round).
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Xe MRI and 3He MRI of COPD is typically characterized by heterogeneous gas

distribution that is reflected in heterogeneous signal intensity for the SV and NDW
images for an inspiration breath-hold scan. To compare the distribution of 129Xe and 3He
gas at different time-points within the lung, segmenting the

129

Xe and 3He images was

based on the voxel signal intensity. A k-means clustering algorithm7 was used to classify
the voxel intensity values into five clusters ranging from signal void (cluster 1, C1 or
ventilation defect volume (VDV)) and hypo-intense (C2) to hyper-intense signal (C5).
Briefly, it involved binning data points into cluster so that the data points in one cluster
were as close to each other in signal intensity as possible and as far as possible from data
points in other clusters. Each cluster was defined by its member objects and the centroid.
The centroids were chosen and through iterations all the data points were binned into
clusters so the all the pixels in a particular cluster were within a range of signal intensity
values. An expert observer can usually distinguish between four visually obvious groups
of signal intensities in pulmonary noble gas MRI- signal void, hypo-intense, normal
intensity and hyper-intense. The static ventilation and the non-diffusion weighted images
were first normalized to the range of pixel intensities 0-255. Following that the full pixel
intensity range of 0-255 was divided into four equal regions: 0-63, 64-127, 128-191, 192255 and the center of each interval was selected as a centroid. After clustering, it was
noticed that the cluster representing signal void contained some pixels with hypo-intense
signal. Hence, the first cluster was divided into four clusters and k-means was reapplied
to it. The first two clusters of the resulting binning were classified as signal void and the
other two clusters as hypo-intense signal, thus giving 5 clusters from C1-C5. C1 included
the minimum signal intensity regions within the lungs as well as the background. A
seeded region growing algorithm8 (SGRA) was used to segment out the thoracic cavity
volume from the 1H images.

The clustered

129

Xe/3He NDW and SV images were

registered to the segmented thoracic cavity to exclude all the pixels in the background
from C1 and only the pixels inside the thoracic cavity were included to generate C1-C5.
For the purpose of analysis, the lung was divided into two regions- regions of signal void
know as ventilation defect volume (VDV) or C1 and the regions of signal intensity
known as ventilation volume (VV) obtained by combining C2-C5. For each

129

Xe/3He

NDW and SV image, the VDV and the VV were normalized to the thoracic cavity
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volume to get a ventilation defect percent (VDP) value and the percent ventilation
volume (PVV) value respectively.
For the 1H images, before applying the SRGA a two-dimensional radially
symmetric Gaussian low-pass filter was applied to reduce the effects of intrapulmonary
vasculature on the thoracic cavity segmentation. A threshold based on the k-means
algorithm was selected to convert the 1H images into a thoracic cavity binary mask.
Following that, initial seed points were automatically selected in both the lungs by
finding columns in the binary mask containing 20 vertically adjacent pixels below the
threshold and the SRGA was used to generate the thoracic mask.
For the registration process, a landmark-based affine transform consisting of
rotation, translation and scaling operations was used to transform the 1H images to
register them to the 129Xe/3He images. Briefly, the center slices (defined as the slices that
clearly showed the carina and primary bronchi) of the 1H and

129

Xe/3He were first

displayed side-by-side and the user was prompted to select 3-7 fiducial markers on both
the slices. Geometric operations consisting of rotation, scaling and translation were used
to transform the 1H image to align it with the corresponding landmarks on the 129Xe/3He
image. The same transformation map was then applied to the rest of the slices to register
all the 1H slices to the corresponding 129Xe/3He slices.
The segmentation included manual steps to select the center slices for the proton
and the

129

Xe/3He images. The center slice was defines as the slice that clearly showed

the trachea, carina and the main two bronchi. The other proton and 129Xe/3He slices were
matched with each other depending on the center slices and the number of slices. The
user also had to select the fiducial points for the registration step for registration of the
proton and

129

Xe/3He center slices. The same transformation was then applied to all the

slices to register the proton slices to the

129

Xe/3He slices. There was also a provision in

the software for the user to manually include or exclude areas from the analysis
depending on the anatomical information. The segmentation and the registration process
is illustrated in Figure 2.4.
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Figure 2.4 Schematic showing the semi-automated segmentation and registration process
for 129Xe static ventilation and 1H images.
Adapted from Kirby et.al. (2012)6
The signal-to-noise ratio (SNR) for all the 129Xe and 3He slices was determined by
calculating the mean voxel signal value within a 5 x 5 cm2 voxel region of interest (ROI)
for n representative ROIs inside the lung parenchyma, and dividing by the standard
deviation of the voxel values for noise inside the same number of representative ROIs of
the same dimensions in the image background where no lung structure was present. The
ROIs within the lung parenchyma and the image background were selected independently
and randomly for each slice.

2.5

Statistical Methods
A repeated measures analysis of variance (ANOVA) was used to determine the

main effects for repeated scans for VDP using IBM SPSS Statistics 20.0 (SPSS Inc.,
Chicago, IL, USA). A two way mixed model intraclass correlation coefficient (ICC)9
analysis under absolute agreement was used to determine the degree of agreement
between different visits. The ICC is a statistical analysis of agreement between two or

62

more measurements and the coefficient represents the agreement between those
measurements. Coefficient of variation (COV) analysis was included in the study to
determine the variability between repeated scans and observers. COV is a coefficient
calculated as the standard deviation of the measurement as the percentage of its mean and
lower COV values represent lower variability between measurements. Linear regression
(r2) and Pearson correlation coefficients (r) were used to determine the relationship
between VDP values at different time-points, relationship between SNR and VDP,
relationship between 2D and 3D image acquisition methods as well as the relationship
between VDP and pulmonary function test measurements using GraphPad Prism version
4.00 ( GraphPad Software Inc, San Diego, CA, USA). In all statistical analyses, results
were considered significant when the probability of making a Type I error was less than
5% (p<.05).
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CHAPTER 3: RESULTS
This chapter describes the results of the analysis described in the previous

chapter. It describes the results of the reproducibility study for hyperpolarized

129

Xe

ventilation defect percent (VDP) measurement for same day rescan (scan and 2-minute
rescan) as well as 1-week rescan (scan, 2-minute rescan and 1-week rescan) for healthy
volunteers and COPD subjects for intra-observer and inter-observer reproducibility. It
also shows results for differences in VDP measurements for scans acquired using 2D and
3D acquisition methods. Also, we compare the reproducibility of

129

Xe VDP to the

reproducibility of 3He VDP.

3.1

Subject Demographics
Five healthy volunteers and ten COPD subjects (GOLD Stage I n=1; II n= 5; III

n=3; IV n=1) were enrolled in the study. Table 3.1 shows the subject demographics
including the pulmonary function test results acquired at baseline (visit 1) for all the
subjects. No significant differences (p > 0.05) were observed between the healthy group
and the COPD subjects for age or body mass index (BMI). Significant differences were
observed between the two groups for FEV1%pred (p < 0.001), FEV1/FVC (p < 0.001), TLC
%pred

(p < 0.01), RV%pred (p < 0.01), FRC%pred (p = 0.02) and DLCO %pred (p = 0.01) but not

for FVC%pred (p = 0.2), RV/TLC (p = 0.06) and IC%pred (p = 0.14). There were no
significant differences in the FEV1 and FEV1/FVC values between the two visits for the
three COPD subjects that returned for the 1-week rescan. Three male HV and eight male
COPD subjects were included in the study.
One COPD subject had a mild adverse effect in the 24 hour period following the
study visit, but was judged not related to the imaging procedure, the details of which are
reported elsewhere.1

It resolved spontaneously, was asymptomatic (no clinical

symptoms) and did not require withdrawal from the study. There were no other scanning
or breath-hold related adverse effects reported in the study.
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Table 3.1 Subject Demographics
Healthy
(n=5)

Parameter

COPD
(n=10)

P Value

Age yrs (±SD)
68 (12)
74 (4)
0.18
Male Sex n
3
8
-2
BMI kg·m (±SD)
27 (2)
25 (5)
0.5
FEV1 %pred (±SD)
105 (7)
57 (24)
0.001
FVC %pred (±SD)
104 (8)
91 (19)
0.2
FEV1/FVC (±SD)
.75 (.02)
.46 (.14)
0.001
TLC %pred (±SD)
101 (7)
115 (8)
0.01
RV%pred (±SD)
100 (9)
159 (46)
0.01
RV/TLC (±SD)
.38 (.08)
.53 (.14)
0.06
IC %pred (±SD)
108 (18)
85 (31)
0.14
FRC%pred (±SD)
95 (14)
141 (35)
0.02
DLCO %pred (±SD)
99 (15)
54 (32)*
0.01
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity,
RV= Reserve Volume, IC= Inspiratory Capacity, FRC= Functional Residual Capacity,
DLCO=Carbon Monoxide Diffusion Capacity of the lung *n=9 (One subject was not able
to complete the DLCO maneuver hence data available for nine of the ten subjects)

3.2

129

Xe MRI Baseline Measurements

Figure 3.1 shows the center slice ventilation distribution for representative
healthy volunteers and COPD subjects for

129

Xe and 3He scans and the differences in

ventilation observed using the two contrast agents.

Visually, elevated defects were

observed for 129Xe MRI as compared to 3He MRI for the same subjects for scans acquired
within a few minutes of each other. Table 3.2 shows the average whole lung VDP values
for the 15 subjects included in the study over the 5 rounds for hyperpolarized
3

He baseline NDW images for observer 1.

Quantitatively too,

129

Xe and

129

Xe VDP was

consistently higher than 3He VDP for all the rounds which is consistent with previously
reported observations.2

Figure 3.2 shows a bar graph with mean

129

Xe VDP

measurements for healthy volunteers and COPD subjects for each of the five rounds of
VDP analysis for baseline NDW images. Repeated measures ANOVA failed to show
any significant differences in VDP measurements over the five rounds for healthy
volunteers or COPD subjects.
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Figure 3.1 Non Diffusion Weighted (NDW) and static ventilation (SV) center slice images
for 129Xe and 3He MRI for healthy volunteers and COPD subjects
Healthy subject S1 is a 26 year old female (FEV1%pred = 92% and FEV1/FVC = 0.91) and S2
is a 69 year old male (FEV
FEV1%pred = 101% and FEV1/FVC = 0.75)
COPD subject S1 is a 77 year old female stage 3 COPD subject with FEV1%pred = 50 and
FEV1/FVC = 50, S2 is a 79 year old male stage 2 COPD subject with FEV1%pred = 52 and
FEV1/FVC = 36
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Table 3.2 Mean values for VDP for a single observer for healthy volunteers and COPD
subjects for 129Xe and 3He over 5 rounds of analysis of baseline NDW images
129

Round 1
Round 2
Round 3
Round 4
Round 5

Mean (±SD)
Mean (±SD)
Mean (±SD)
Mean (±SD)
Mean (±SD)

Xe MRI VDP (%)
(n=15)
26 (18)
26 (17)
27 (17)
25 (18)
25 (18)

3

He MRI VDP (%)
(n=15)
16 (14)
17 (14)
17 (13)
17 (14)
17 (14)

Figure 3.2 129Xe NDW VDP for Healthy Volunteers and COPD subjects
Bar graphs showing mean 129Xe VDP for baseline NDW images for (A) Healthy
volunteers (B) COPD subjects. No significant differences (p > 0.05) were observed
between the 5 rounds for healthy volunteers or COPD subjects.

The ventilation defects observed using hyperpolarized noble gases have previously been
shown to be spatially related to pulmonary structural abnormalities, detected using CT
and histology in COPD and lung cancer patients.3,4 This suggests that the abnormal
ventilation pattern observed in COPD subjects using hyperpolarized noble gas imaging, is
due to structural abnormalities in these subjects.
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We compared the

129

Xe MRI VDP obtained from scans acquired using a 2D

FGRE pulse sequence and a 3D FGRE pulse sequence for scans done within 10 minutes
of each other for the same set of subjects. We compared the VDP from NDW images
obtained using a 2D FGRE sequence with VDP from SV images obtained with a 3D
FGRE sequence. Figure 3.3 shows the relationship of VDP from the NDW and the SV
images. A strong and significant correlation was obtained between the two time points
and repeated measures ANOVA failed to show any significant difference between scans
obtained using 2D and 3D pulse sequences (p = 0.496). Intra-class correlation coefficient
analysis showed significant and strong correlation between the 2D and 3D scans over 5
rounds of analysis (ICC = 0.914)

Figure 3.3 Relationship between pulse sequences for VDP
Relationship between 2D and 3D acquisition methods for 129Xe MRI VDP. Solid line =
mean difference, dashed line = 95% confidence intervals of regression line. 2D
acquisition shows significant and positive correlation with 3D acquisition (r2 = 0.75,
p < 0.0001; y = 0.97x + 2.17)
We also investigated the relationship between signal to noise ratio (SNR) and
VDP to see if the differences in SNR between repeated scans were responsible for
differences in VDP.

We found that there was no significant relationship observed

between SNR and VDP (p = 0.95) for the 15 subjects. Figure 3.4 shows the relationship
for SNR and VDP.
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Figure 3.4 Relationship between 129Xe VDP and SNR
Relationship between SNR and VDP for 129Xe MRI. Solid line = mean difference, dashed
line = 95% confidence intervals of regression line. VDP shows no significant correlation
with SNR (r2 = 0.00002, p = 0.95; y = 0.005x + 22.85)
We analyzed the reproducibility of

129

Xe MRI VDP measurements over short

periods of time (same day rescan and 1-week rescan) when no pulmonary physiological
changes were expected to occur in the subjects. Two independent observers analyzed the
NDW and SV images for VDP. Observer 1 analyzed the
images 5 times (5 rounds) while observer 2 analyzed the
round).

129

Xe and 3He NDW and SV

129

Xe NDW images once (1

These data were then used to study the intra-observer and inter-observer

reproducibility for 129Xe MRI VDP.

3.3

Comparison of reproducibility of 129Xe MRI VDP and 3He MRI
VDP
Table 3.3 shows the repeated measures ANOVA p values for

129

Xe MRI VDP

and 3He MRI VDP for same day rescan for observer 1 over 5 rounds of VDP analysis.
The p values failed to show any significant differences between the same day rescan for
129

Xe or 3He VDP. The ANOVA also failed to show any significant difference between
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the 5 rounds of VDP analysis for either contrast agent. The interaction between the
rounds and scans was also found to be not significant.
129

Xe MRI (P value)

3

He MRI (P Value)

Same-day (n=15)

Same-day (n=15)

Rounds

0.162

0.105

Scans

0.878

0.138

Rounds * Scans

0.404

0.108

Table 3.3 Repeated measures ANOVA for 129Xe VDP and 3He VDP for same day rescan
Same-day = Same day rescan

Table 3.4 shows ICC values for
VDP same day rescan. Both

129

129

Xe VDP same day rescan as well as 3He MRI

Xe MRI VDP and 3He MRI VDP showed strong and

significant ICC values. Table 3.4 also slows COV values for observer 1 and observer 2
for

129

Xe MRI VDP same day rescan and 3He MRI VDP for observer 1 for same day

rescan for all the 15 healthy volunteers and COPD subjects.

Table 3.4 ICC and COV analysis for

129

Xe MRI VDP and 3He MRI VDP for same day

rescan
129

Xe MRI

3

He MRI

Same-day (n=15)

Same-day (n=15)

0.949 (<.0001)

0.962 (<.0001)

COV (Obs 1) (%)

11

14

COV (Obs 2) (%)
Same-day = Same day rescan

10

-

ICC
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3.4

129

Xe MRI Intra-Observer Reproducibility

Figure 3.5 shows the ventilation distribution for

129

Xe NDW scans for three

COPD subjects who had two NDW scans at visit 1 (baseline scan, 2-minute rescan) and
repeated NDW scans (scan, 2-minute rescan) one week later. The center slices for the
NDW 129Xe MRI scans are shown in the figure for baseline scan, same day rescan and 1week rescan.

The ventilation distribution is highly heterogeneous for these COPD

subjects and the location of defects is visually consistent over the three time points. The
three subjects showed no significant differences in spirometry (FEV1, FVC or
FEV1/FVC) between the two visits separated by a period of 1 week. The repeated NDW
scans were used to access the reproducibility of hyperpolarized

129

Xe MRI VDP. Data

from the 15 subjects who had the scan and 2-minute rescan were used to study the same
day reproducibility of

129

Xe VDP while data from the three COPD subjects who had the

scan, 2-minute rescan and 1-week rescan were used to study the 1 week reproducibility.

72

Figure 3.5 129Xe NDW images over three time points for three COPD subjects
Subject S1 is a 79 year old male stage 2 subject with FEV1%pred = 52 and FEV1/FVC = 36
Subject S2 is a 76 year old male stage 2 subject with FEV1%pred = 77 and FEV1/FVC = 54
Subject S3 is a 73 year old male stage 4 subject with FEV1%pred = 26 and FEV1/FVC = 29
Same dayy = Same day rescan, 1 Week = 11-week rescan
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Table 3.5 shows repeated measures ANOVA P values for

129

Xe VDP for same

day reproducibility (baseline NDW scan, 2-minute NDW rescan) for 15 subjects. It also
shows results for 1-week reproducibility (baseline NDW scan, 2-minute NDW rescan and
1-week NDW rescan) for 3 subjects. The table shows the main effects for 5 rounds of
VDP analysis by observer 1 and the main effects for repeated scans, as well as the
interaction between the 5 rounds and scans. The ANOVA failed to show any significant
main effects for the 5 repeated rounds of VDP analysis or the repeated scans of

129

Xe

MRI. The interaction between the rounds and the scans was also not significant for
same-day rescan or 1-week rescan.
Table 3.5 Repeated measures ANOVA for intra-observer reproducibility: 129Xe VDP
same day rescan and 1-week rescan
129

Xe MRI (P value)

Same-day (n=15)

1-Week (n=3)

Rounds

0.162

0.284

Scans

0.878

0.127

Rounds * Scans
0.404
Same-day = Same day rescan, 1-Week = 1-week rescan
ICC analysis for the repeated

129

0.315

Xe scans is shown in Table 3.6. Strong and

significant ICC values were observed for all the 129Xe repeated scans. The 1-week rescan
showed a slightly weaker correlation compared to the same day rescan although the
correlation was significant and strong (ICC = 0.861). The COV analysis for

129

Xe VDP

for the same day rescan for observer 1 and observer 2 is shown in Table 3.6. The table
also shows the COV analysis for the 1-week rescan for both the observers.
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Table 3.6 ICC and COV Analysis for intra-observer reproducibility: 129Xe VDP same day
rescan and 1-week rescan
129

ICC
COV (Obs 1) (%)

Xe MRI

Same-day (n=15)

1-Week (n=3)

0.949 (<.0001)

0.861 (<.0001)

11

13

COV (Obs 2) (%)
10
13
ICC = Intra class correlation coefficient, COV = Coefficient of Variation. Numbers in
parentheses are P values, Obs 1= Observer 1, Obs 2= Observer 2
Same day = Same day rescan, 1-Week = 1-week rescan
Figure 3.6 shows relationship for 129Xe NDW scans over multiple time points. It
shows the correlation for the baseline scan VDP with the same day rescan VDP for
observer 1 over 5 rounds. Strong and significant correlation was observed for this
comparison. It also shows the correlation for the baseline NDW scans with the NDW
scans obtained one week later for three COPD subjects. For this comparison too, strong
and significant correlation was observed.

Figure 3.6 Relationship between repeated scans for VDP
Relationship between same day and 1-week repeated scans for 129Xe MRI VDP. Solid
line = mean difference, dashed line = 95% confidence intervals of regression line.
A) Significant and strong correlation between scan and same-day rescan (r2 = 0.83,
p < 0.0001; y = 0.87x + 2.03), B) Significant and strong correlation between scan and 1week rescan (r2 = 0.83, p < 0.0001; y = 1.01x + 6.22)

75

3.5

129

Xe MRI Inter-Observer Reproducibility

To evaluate the inter-observer reproducibility for hyperpolarized 129Xe MRI VDP,
a second observer analyzed the repeated

129

Xe NDW MR images for VDP. Repeated

measures ANOVA failed to show significant differences between the two observers or
between repeated scans for the same day rescan or the 1-week rescan as shown by the
non significant p values in Table 3.7. The interaction between the observers and the
scans was also not significant for same day rescan or the 1-week rescan.
Table 3.7 Repeated Measures ANOVA for inter-observer reproducibility: 129Xe VDP
same day rescan and 1-week rescan
129

Xe MRI (P value)

Same-day (n=15)

1-Week (n=3)

Observers

0.550

0.205

Scans

0.877

0.143

Observers * Scans
0.823
Same-day = Same day rescan, 1-Week = 1-week rescan

0.368

Table 3.8 shows the ICC and COV values for inter-observer reproducibility
analysis for two observers for repeated scans for same day rescan and 1-week rescan.
Significant and high ICC values were observed for both the comparisons.
Table 3.8 ICC and COV for inter-observer reproducibility: 129Xe VDP same day rescan
and 1-week rescan
129

ICC

Xe MRI

Same-day (n=15)

1-Week (n=3)

0.978 (< .0001)

0.929 (< .0001)

COV (%)
11
11
ICC = Intraclass correlation coefficient, COV = Coefficient of Variation. Numbers in
parentheses are P values. Same day = Same day rescan, 1-Week = 1-Week rescan
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Figure 3.7 shows the inter-observer relationships for same day rescan for
VDP as well as the 1-week rescan for

129

129

Xe

Xe VDP. Significant and strong correlations

were observed for both the comparisons.

Figure 3.7 Inter-observer correlations for 129Xe VDP
Obs 1 = Observer 1, Obs 2= Observer 2
Relationship between VDP analysis by two observers for 129Xe MRI. Solid line = mean
difference, dashed line = 95% confidence intervals of regression line. A) Significant and
strong correlation between observers for same-day rescan (r2 = 0.98, p < 0.0001;
y = 0.91x + 2.02), B) Significant and strong correlation between observers for 1-week
rescan (r2 = 0.99, p < 0.0001; y = 0.97x + 1.40)

3.6

129

Xe MRI VDP relationship to pulmonary function
measurements
Significant and strong correlations were observed between baseline NDW

129

Xe

VDP values and the gold standard measurements for obstructive lung disease diagnosisFEV1%pred and FEV1/FVC as shown in Figure 3.8. Significant and moderate to strong
correlations were also observed between VDP and lung volume measurements like RV
(r2 = 0.91), RV/TLC (r2 = 0.55) and FRC (r2 = 0.80).

A significant and strong

relationship was also observed between VDP and DLco (r2 = 0.74). Significant and
moderate correlations were observed between VDP and TLC (r2 = 0.59) and IC (r2 =
0.52) but not with FVC (r2 = 0.23, p = 0.07).
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Figure 3.8 129Xe baseline NDW VDP correlations with pulmonary function tests
Relationship between VDP and PFT measurements for all 15 subjects. Solid line = mean
difference, dashed line = 95% confidence intervals of regression line. A) Significant and strong
correlation between VDP and FEV1 (% pred) (r2 = 0.80, p < 0.0001; y = -0.50x + 64.9),
B) Significant and strong correlation between VDP and FEV1/FVC (r2 = 0.91, p < 0.0001;
y = -0.89x + 77.57), C) Significant and strong correlation between VDP and RV (r2 = 0.71,
p < 0.0001; y = 0.31x -14.92), D) Significant and moderate correlation between VDP and
RV /TLC (r2 = 0.55, p = 0.0015; y = 0.92x -16.01), E) Significant and strong correlation
between VDP and FRC (r2 = 0.80, p < 0.0001; y = 0.42x -24.72), F) Significant and strong
correlation between VDP and DLCO (r2 = 0.74, p < 0.0001; y = -0.42x + 56.58),
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4

CHAPTER 4: DISCUSSION AND FUTURE WORK
In this final chapter, I will highlight all the important findings from this

reproducibility study of hyperpolarized

129

Xe MRI VDP measurement. A discussion of

the relevance of this work is presented based on the results from Chapter 3. Finally, the
limitations of the study are presented followed by the future directions for this work and
the conclusion for this study.
To our knowledge, this is the first study that looks at the reproducibility of
hyperpolarized

129

Xe MRI VDP. We report: 1) No significant differences in VDP for

scans acquired using a 2D FGRE pulse sequence compared to scans acquired using a 3D
FGRE pulse sequence, 2) No correlation between SNR and VDP for
Visual and quantitative evidence of elevated defects using

129

129

Xe MRI, 3)

Xe as a contrast agent

compared to 3He, 4) High intra-observer reproducibility for 129Xe VDP and 3He VDP for
same day rescan, 5) High intra-observer reproducibility for 129Xe VDP for same day and
1-week rescan, 6) High inter-observer reproducibility for 129Xe VDP for same day and 1week rescan, 7) Significant and strong correlation between

129

Xe VDP and pulmonary

function test measurements.

4.1

129

Xe MRI Baseline Measurements

For the

129

Xe MRI scans, I compared the VDP obtained using a 2D FGRE pulse

sequence with the VDP obtained using a 3D FGRE pulse sequence, for the same subjects
for scans acquired within a few minutes of each other. NDW images acquired using a 2D
FGRE sequence were compared with SV images acquired using a 3D FGRE sequence.
The major difference between the 2D and the 3D FGRE pulse sequence was that in the
3D acquisition, magnetic resonance data was acquired from a volume rather than a single
tomographic slice. An additional phase encode pulse was applied in the 3D acquisition to
image a greater thickness of tissue compared to the 2D acquisition. Repeated measures
ANOVA failed to show any significant differences for

129

Xe VDP between 2D FGRE

and 3D FGRE scans acquired within a few minutes of each other. Significant and strong
ICC values were observed for the comparison of 5 rounds of NDW and SV image
analysis. The ICC is a statistical analysis of agreement between two measurements, and

80

the coefficient represents the agreement in VDP values for observer 1 between the 2D
acquisition and the 3D acquisition for same day rescan. A strong ICC value, as was
observed for the NDW scan and SV same day rescan for

129

Xe VDP, represents a good

agreement between the VDP values obtained at the two time-points using the two
different pulse sequences.

A significant and strong correlation was also observed

between the VDP values for scans acquired using the two image acquisition methods. 3D
acquisition typically provides a better SNR for imaging lung ventilation with
hyperpolarized noble gases as well as better spatial resolution.1 Therefore, 3D sequences
will be useful for studies that need to accurately calculate the ventilation volume and
ventilation defect volume which requires high spatial resolution in all three dimensions.
I also investigated the relationship between SNR and VDP for

129

Xe MRI, to see

if the differences in SNR between repeated scans were responsible for differences in
VDP values. It is important to investigate this relationship because typically 129Xe MRI
images are of a lower SNR than 3He images due to the differences in the physical
properties between the two gases. Also, repeated scans using the same contrast agent can
have large variations in SNR depending on the imaging procedure used, including the
scanner and pulse sequence, polarization of the gas itself and the breath-hold maneuver
performed by the subject. We found that there was no significant relationship observed
between SNR and VDP (p = 0.95) for the 15 subjects included in the study. These results
suggest that the differences in SNR between repeated scans were not responsible for
differences in VDP values. This is an important observation since SNR values can vary
to a great degree and the reproducibility of the VDP measurement would be affected if
SNR had an effect on the VDP measurement.

4.2

Comparison of reproducibility of 129Xe MRI VDP and 3He MRI
VDP
We compared the reproducibility of hyperpolarized

129

Xe MRI VDP with the

reproducibility of 3He MRI VDP. First, both visually and quantitatively,

129

Xe MRI

showed elevated defects as compared to 3He MRI for the same set of subjects for scans
acquired within 10 minutes of each other, which is consistent with previously reported
observations.2,3 The differences in the physical properties of 129Xe and 3He may provide
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an explanation for this observation.

Kirby et al. reported that the lower diffusion

coefficient of 129Xe compared to 3He may be responsible for slower filling of 129Xe in the
diseased lung regions, leading to elevated defects observed in

129

Xe MRI.2 Previous

studies have reported that 3He MRI measurements are reproducible over short periods of
time in healthy volunteers and subjects with obstructive lung disease.4-8 It is important to
study if the differences in the physical properties of the two gases are reflected as
differences in the reproducibility of
3

129

Xe MRI VDP compared to the reproducibility of

He MRI VDP.
For the same set of subjects, repeated measures ANOVA failed to show any

significant differences in VDP values for repeated

129

Xe MRI scans as well as 3He MRI

scans for same day rescan (scans acquired on the same day within 2 ± 1 minutes of each
other). There were no significant differences in the 5 rounds of repeated VDP analysis
for

129

Xe or 3He MRI indicating good intra-observer reproducibility for same day rescan

for

129

Xe and 3He VDP. Significant and strong ICC values were observed for same day

rescan for both 129Xe VDP and 3He VDP. The ICC is a statistical analysis of agreement
between two measurements, and the coefficient represents the agreement in VDP values
for observer 1 between the scan and the same day rescan. A strong ICC value, as was
observed for the scan and the same day rescan for both 129Xe and 3He, represents a good
agreement between the VDP values obtained at the two time-points for both the contrast
agents. The COV values for observer 1 and observer 2 were 11% and 10% respectively
for 129Xe VDP, and that for 3He was 14% for observer 1. Observer 2 did not analyze the
3

He images and hence a COV value for observer 2 was not available.

COV is a

measurement of the standard deviation as a percentage of the mean and lower COV
values for 129Xe VDP compared to 3He VDP suggest that there is lower variation in 129Xe
VDP same day rescan compared to 3He VDP same day rescan.

However, this

interpretation should be made with caution using COV analysis as there are major
limitations for this statistical method. For one, COV is the ratio of standard deviation
over mean. The mean values for VDP were observed to be significantly lower for 3He
compared to

129

Xe and hence the COV might not accurately reflect the difference in

variation between the two contrast agents. Secondly, our subject cohort included healthy
volunteers who have low mean VDP values and hence push the COV values up. All
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factors considered, this analysis suggests that the intra-observer reproducibility of

129

Xe

MRI VDP and 3He MRI VDP is high for same day rescan for healthy volunteers and
subjects with COPD.

4.3

129

Xe MRI Intra-Observer Reproducibility

We analyzed the intra-observer reproducibility of 129Xe VDP for same day rescan
(scan, 2- minute rescan) and 1-week rescan (scan, 2-minute rescan and 1 week rescan) for
5 rounds of VDP analysis. For the same day rescan, a repeated measures ANOVA failed
to show any significant differences between the VDP values for repeated scans for the
cohort of 15 subjects, which included healthy and COPD subjects. There are several
sources of variation for scans acquired within 2 minutes of each other, such as 1) subject
compliance (breath-hold, motion), 2) polarization of the gas and gas delivery methods, 3)
observer dependence in the semi-automated segmentation software.

We tried to

minimize the variation in repeat scans due to subject compliance by giving the subjects
extensive coaching regarding inhalation of the contrast agent and the breath-hold
requirements. The observer variation in the segmentation and registration steps was
minimized by giving the observers extensive training regarding the use of the semiautomated segmentation software.

These results suggest that the

129

Xe VDP

measurement is robust to variations between scans acquired over short periods of time.
The ANOVA also failed to show any significant difference between the 5 rounds of VDP
analysis for the single observer for same day rescan. This suggests high intra-observer
reproducibility for the VDP measurement for same day rescan of
value for same day rescan for

129

129

Xe MRI. The ICC

Xe VDP was significant and strong indicating good

agreement between the VDP values for the repeated scans. The COV values for same
day rescan were 11% and 10% for the two observers. The COV values were higher than
previously reported COV values for 3He VDV for COPD subjects.9 However, this
subject cohort included healthy subjects along with COPD subjects, who on account of
their lower mean VDP values push the COV values higher. The COV values observed
for 129Xe VDP for same day rescan were lower than those for 3He VDP same day rescan
for the same subject cohort.

These results suggest that

129

Xe MRI VDP is highly

reproducible for same day rescan when no physiological pulmonary changes are expected
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to occur. The measurement is robust to variations in subject compliance, polarization of
the gas as well as the observer error in the semi-automated segmentation method for
scans acquired within a few minutes of each other.
For the 1-week rescan reproducibility, the ANOVA failed to show any significant
differences between the scan, 2 minute rescan and 1-week rescan for the three COPD
subjects that had the 1-week repeat scan. Visually too, the defects appeared consistent
over the three repeated scans. There are several sources of variation for scans acquired 1week from each other, such as 1) subject compliance (breath-hold, motion), 2)
polarization of the gas and gas delivery methods, 3) scanner 4) position of the coil within
the bore of the MRI 5) observer dependence in the semi-automated segmentation
software, 6) potential physiological changes. An effort was made to keep the variation in
the position of the coil inside the bore of the scanner to a minimum between the scans.
The three COPD subjects showed no significant differences in spirometry (FEV1, FVC or
FEV1/FVC) between the two visits separated by a period of 1-week suggesting that no
significant global change in respiratory function had taken place over the one week
period.

These results suggest that the

129

Xe MRI VDP measurement is robust to

variations in scans over a period of one week. This implies that the

129

Xe MRI VDP

measurement is reproducible over longer periods of time and can cope with variations
arising from various sources like the patient, scanner, contrast agent as well as the
observer analyzing the images. The repeated measures ANOVA failed to show any
significant differences in the 5 repeated rounds of VDP analysis for the 1-week rescan.
This suggests that 129Xe MRI VDP shows good intra-observer reproducibility for 1-week
repeated scan. Significant and strong ICC values were observed for the 1-week rescan
for 129Xe VDP indicating good agreement between the VDP values for the three repeated
scans. The COV for the 1 week rescan was 13% for both the observers who analyzed the
129

Xe repeated scans. Significant and strong correlation values were observed for same

day rescan and 1-week rescan.
In order to be confident about the physiological changes and biological
phenomenon observed in the subject, we should be confident that the source of the
variation in the measurement is from the subject (physiological change) and not from any
stage of the imaging procedure. The results for the intra-observer reproducibility suggest
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that 129Xe MRI VDP is a highly reproducible measurement over same day rescans as well
as over 1-week rescans and can be used as a reliable measurement for pulmonary imaging
studies.

4.4

129

Xe MRI Inter-Observer Reproducibility

Two independent observers analyzed the

129

Xe same day and 1-week repeated

scans for evaluation of inter-observer reproducibility of VDP measurement. For the same
day rescan, a repeated measures ANOVA failed to show any significant differences in
VDP measurement between the two observers. Also, the ANOVA failed to show any
significant differences between the repeated scans for the same day rescan for either
observer. For the 1-week rescan too, it failed to show any significant differences in VDP
between the two observers. As well as the scan, the same day rescan and the 1-week
rescan. The segmentation software used for the calculation of VDP is semi-automated
with the observer providing input regarding which areas of the lung are classified as
defects and also has to select fiducials for the registration step. These results suggest that
the inter-observer variability in this process is not significant between observers and
different observers analyze the images in a consistent way, when properly trained to use
the software. This suggests that the VDP measurement can be reliably used in multiobserver or even multi-center research studies if the observers are properly trained. The
ICC value showed a significant and strong agreement between the two observers for the
scan and same day scan as well as the scan, same day rescan and 1-week rescan. The
COV was observed to be 11% between the two observers for both the scan and same day
rescan as well as the scan, same day rescan and 1-week rescan. Although this COV value
seems high, it has to be considered that the subject cohort contains healthy volunteers
who push the COV value up because of their low mean VDP. The correlation coefficient
between the two observers for VDP measurement was found to be significant and strong
for the scan and same day rescan and the scan, same day rescan and 1-week rescan.
These results suggest that the inter-observer reproducibility for 129Xe VDP is high and the
measurement can be reliably used in multi-observer and multi-center studies.
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4.5

129

Xe MRI VDP relationship to Pulmonary Function
Measurements
We evaluated the relationship between VDP and all the pulmonary function test

measurements. There was a strong and significant inverse correlation between VDP and
the gold standard measurement for obstructive lung disease diagnosis – FEV1/FVC.
Significant and strong inverse correlation was also observed between VDP and FEV1%pred
but a significant relationship was not observed between VDP and FVC%

pred.

Subjects

with obstructive lung disease have a reduced FEV1/FVC ratio because of airway
narrowing caused by a lot of factors including thickening and obliteration of airways and
small airways disease.

FEV1/FVC reduction in obstructive lung disease has been

reported to be sensitive to airway narrowing and bronchoconstriction.10 The significant
and strong correlation of VDP with FEV1/FVC suggests that VDP can be a very useful
tool for studying the different airway and parenchymal abnormalities in obstructive lung
disease. FEV1%pred value is used for the classification of COPD subjects into different
stages, depending on the severity of the disease.11 A significant and strong correlation
between 129Xe VDP and FEV1%pred suggests that VDP can be used to classify subjects into
stages depending on the ventilation abnormalities and VDP values. Similar relationships
between ventilation defects and spirometric measurements have been previously reported
in obstructive lung disease using 3He and

129

Xe MRI measurments.2,12,13 We also

observed a significant and strong positive correlation between

129

Xe VDP and RV. In

COPD patients, the RV values increases markedly due to “gas trapping” in the alveoli.
Gas trapping is caused by the decrease in the elastic recoil of the lungs due to fibrosis as
well as the collapse of the bronchioles during expiration leading to large amounts of air
being trapped in the alveoli. The significant and strong correlation between

129

Xe VDP

and RV suggests that VDP might be a good tool for diagnosis of gas trapping in patients
suffering from COPD.

There was also a significant and strong inverse correlation

between VDP and DLCO observed. DLCO is a surrogate measurement for the diffusion of
oxygen across the alveolar membrane into the blood. The strong correlation suggests that
VDP might be a good indicator of emphysema in subjects suffering from COPD. The
strong correlations observed between

129

Xe MRI VDP and the pulmonary function test
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measurements suggest that VDP might be a useful tool for obstructive lung disease
diagnosis, monitoring disease progression and evaluating response to treatment.

4.6

Study Limitations
We acknowledge that this work was limited due to the small number of subjects

included in the study, especially for the 1-week rescan. Since we had a small subject
size, caution should be exercised when extrapolating these results to the general COPD
population and other obstructive and restrictive lung disease populations. We did not
evaluate the reproducibility of

129

Xe MRI VDP in other obstructive and restrictive lung

diseases other than COPD. For the COPD subjects who returned for the 1-week rescan,
we did not acquire proton scans at the 1-week rescan and had to use proton scans from
the baseline visit. Although the shape and size of the thoracic cavity is not expected to
change significantly over a one week period, this could potentially be a source of error
for the 1-week rescan VDP.

Another limitation of the study is that we did not acquire

repeated 3He MRI scans for 1-week rescan for the three COPD subjects and hence a
direct comparison between

129

Xe VDP and 3He VDP for 1-week rescan reproducibility

could not be made.

4.7

Future Work
The results and discussions presented in this thesis provide some important

insights in the intra-observer and inter-observer reproducibility of hyperpolarized

129

Xe

MRI VDP measurement and provide the foundation for future work. The reproducibility
of

129

Xe VDP measurement needs to be evaluated in other pulmonary diseases like

asthma, CF and RILI. The reproducibility of

129

Xe MRI ADC measurement, used to

probe the lung microstructure, needs to be evaluated for obstructive and restrictive lung
diseases.
Over the last two decades, there has been tremendous progress made in
understanding structural and functional changes in pulmonary diseases using
hyperpolarized 3He MRI. However, due to the limited availability and high cost of 3He,
its clinical translation has not been possible.

129

Xe is more abundant and cheaper and

hence is a much more realistic option as a contrast agent in clinical applications.
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However, due to the differences in the physical properties between

129

Xe and 3He, many

of the studies and work performed using 3He will have to be reproduced using
While recently there have been studies performed comparing

129

129

Xe.

Xe and 3He MRI

measurements in healthy volunteers and subjects with pulmonary diseases,2,3,14 there is a
need to perform more studies using
the physical properties of

129

129

Xe MRI probing the effects of the differences in

Xe in comparison to

3

He on pulmonary imaging

measurements.

4.8

Conclusion
The development of pulmonary imaging techniques has led to advancements in

our understanding of pulmonary structural and functional changes associated with
pulmonary disease. Spirometry and plethysmography, which provide gold standards
measurements for obstructive lung disease diagnosis, are limited because they provide
only a global measurement of lung function in regionally highly heterogeneous diseases
like COPD and asthma and are insensitive to early stages of the disease. CT, the gold
standard for pulmonary lung structure evaluation, is limited by its high radiation dose and
its inability to provide regional functional information in pulmonary disease.
Hyperpolarized noble gas magnetic resonance imaging (MRI) has emerged as a noninvasive, non-radiation based sensitive tool for visualizing the regional lung structure and
function.

129

Xe is one of the contrast agents that can be used for hyperpolarized gas

pulmonary imaging.

However, the reproducibility of hyperpolarized

129

Xe MRI

measurements had not yet been studied or determined. Hence, the aim of this thesis was
to evaluate the reproducibility of hyperpolarized

129

Xe MRI measurements over short

periods of time. Our results show that hyperpolarized

129

Xe MRI VDP has high intra-

observer and inter-observer reproducibility for scans acquired on the same day as well as
after a period of 1-week.

129

Xe MRI VDP also showed strong and significant correlations

with pulmonary function test measurements. These results suggest that hyperpolarized
129

Xe MRI VDP is reproducible over short periods of time and can be used as a reliable

measurement to study pulmonary function in imaging studies. Hyperpolarized

129

Xe

MRI is able to provide pulmonary structural and functional information and has emerged
as a very important tool in pulmonary imaging research studies.
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